text:
- Welcome Guest
- Renew, Subscribe or Create Account
Original Article
The Prevalence of Hepatitis C Virus Infection in the United States, 1988 through 1994
Miriam J. Alter, Ph.D., Deanna Kruszon-Moran, M.S., Omana V. Nainan, Ph.D., Geraldine M. McQuillan, Ph.D., Fengxiang Gao, M.D., Linda A. Moyer, B.S., Richard A. Kaslow, M.D., M.P.H., and Harold S. Margolis, M.D.
N Engl J Med 1999; 341:556-562August 19, 1999
- Abstract
- Article
- References
- Citing Articles (1100)
- Letters
BackgroundBecause many persons with chronic hepatitis C virus (HCV) infection are asymptomatic, population-based serologic studies are needed to estimate the prevalence of the infection and to develop and evaluate prevention efforts.
MethodsWe performed tests for antibody to HCV (anti-HCV) on serum samples from 21,241 persons six years old or older who participated in the third National Health and Nutrition Examination Survey, conducted during 1988 through 1994. We determined the prevalence of HCV RNA by means of nucleic acid amplification and the genotype by means of sequencing.
ResultsThe overall prevalence of anti-HCV was 1.8 percent, corresponding to an estimated 3.9 million persons nationwide (95 percent confidence interval, 3.1 million to 4.8 million) with HCV infection. Sixty-five percent of the persons with HCV infection were 30 to 49 years old. Seventy-four percent were positive for HCV RNA, indicating that an estimated 2.7 million persons in the United States (95 percent confidence interval, 2.4 million to 3.0 million) were chronically infected, of whom 73.7 percent were infected with genotype 1 (56.7 percent with genotype 1a, and 17.0 percent with genotype 1b). Among subjects 17 to 59 years of age, the strongest factors independently associated with HCV infection were illegal drug use and high-risk sexual behavior. Other factors independently associated with infection included poverty, having had 12 or fewer years of education, and having been divorced or separated. Neither sex nor racial–ethnic group was independently associated with HCV infection.
ConclusionsIn the United States, about 2.7 million persons are chronically infected with HCV. People who use illegal drugs or engage in high-risk sexual behavior account for most persons with HCV infection..
Media in This Article
Article Activity
- Hepatitis C virus (HCV) infection is a leading cause of chronic liver disease in the United States. Before the characterization of HCV,1,2 the magnitude of infection could not be reliably determined because assessment of clinical disease (i.e., non-A, non-B hepatitis) underestimated the true extent of infection. After tests to detect antibody to HCV (anti-HCV) became available, studies to determine the prevalence of HCV infection in the general population were performed, mostly with volunteer blood donors as the subjects.3,4 However, the prevalence of HCV among blood donors does not reflect the prevalence in the general population, since even first-time donors are a highly selected group that has been screened for risk factors associated with various infectious diseases. To estimate the true prevalence of HCV infection in the United States, we tested serum samples from participants in the third National Health and Nutrition Examination Survey (NHANES III) for anti-HCV.
Survey Design and Collection of DataThe NHANES is conducted periodically by the National Center for Health Statistics, Centers for Disease Control and Prevention (CDC), to obtain national statistics on the health and nutritional status of the noninstitutionalized civilian population by means of household interviews, standardized physical examinations, and collection and testing of blood samples in special mobile examination centers.5 NHANES III, conducted during 1988 through 1994, included a sample of approximately 40,000 persons at least two months of age at 89 randomly selected locations throughout the United States. The study protocol was reviewed and approved by an institutional review board at the CDC. All participants (or their parents, in the case of children) provided written informed consent.NHANES III was based on a complex, stratified, multistage, probability-sample design.5 Persons less than 5 years of age or 60 years of age or older, blacks, and Mexican Americans were sampled at higher frequencies than other persons. After weighting on the basis of age, sex, level of education, and race or ethnic group, the distribution of participants was similar to that of the U.S. population as a whole.We collected information in interviews on demographic, occupational, and behavioral characteristics. Race or ethnic group was defined by the subjects' choices among the categories non-Hispanic white, non-Hispanic black, and Mexican American. Subjects who did not choose one of these categories were classified as "other" and analyzed with the total population but not in racial–ethnic subgroups. The poverty index was calculated by dividing the total family income by the poverty threshold, as defined by the U.S. Census, with adjustment for family size at the time of the interview. Questions about years of education, marital status, occupation, and military service were asked of participants 17 years of age or older. Questions about sexual behavior and illegal drug use were asked of participants 17 to 59 years old. For illegal drug use, questions were limited to the use of cocaine (including "crack" cocaine) and marijuana and did not include the method of administration or history of injection. The questionnaire also asked about some surgical procedures (e.g., hysterectomy) and the frequency of dental visits, but it did not ask whether the subjects had undergone blood transfusion.
Laboratory MethodsTesting for HCV infection was performed on serum samples collected from subjects at least six years of age who completed the examination component of NHANES III. Serum samples were tested for anti-HCV with use of a second-generation enzyme immunoassay and a supplemental test (EIA 2.0 and HCV MATRIX, Abbott Laboratories, North Chicago, Ill.). Samples that were positive according to HCV MATRIX were considered positive for anti-HCV.Testing for HCV RNA by reverse-transcriptase–polymerase-chain-reaction (RT-PCR) amplification of the 5' noncoding region was performed on anti-HCV–positive samples as described previously.6 Samples found to be negative for HCV RNA were extracted a second time by the same procedure, with an additional incubation at 50°C for 45 minutes with 25 units of reverse transcriptase (Boehringer Mannheim, Indianapolis) and 10 units of RNAsin (Boehringer Mannheim).Nested RT-PCR was used to amplify the 5' noncoding region and the nonstructural coding 5b (NS5b) region with use of previously described primers,6,7 except that R1 (5'GCTCTCAGGCTCGCCGCGTCCTC3') and R2 (5'GCTCTCAGGTTCCGCTGCTCCTC3') were used as internal reverse primers for NS5b amplification. PCR products were separated by electrophoresis on a 2 percent agarose gel, and positive specimens were identified by ethidium bromide staining.6 PCR products were purified and cycle-sequenced with use of internal primers with dye-terminator reaction chemistry. Electrophoresis and nucleotide identification were performed with an automated DNA sequencer (ABI 377, Applied Biosystems, Foster City, Calif.).The genotypes of HCV RNA–positive samples were determined by the sequencing of 300 nucleotides in the NS5b region.7 We compared sequences for each genotype with published sequences, using the Wisconsin Genetic Computer Group program, with use of subprograms Gap and Pileup for pairwise alignment.8Serum samples were also tested for serologic markers of hepatitis B virus (HBV) infection9 and antibody to herpes simplex virus type 2.10,11 Serum alanine aminotransferase activity could not be determined, because the manner in which samples were handled before testing (they were frozen at –20°C and thawed at room temperature) has been shown to result in enzyme degradation.12
Statistical AnalysisEstimates of prevalence were weighted so as to represent the total U.S. population and to account for oversampling and for nonparticipation in the household interview and physical examination.13 Weights were further ratio-adjusted according to age, sex, and race or ethnic group to match estimates of the distribution of these factors in the civilian noninstitutionalized U.S. population, with adjustment for undercounting.13,14 Standard errors were calculated with use of SUDAAN software.15 For comparisons among subgroups of the NHANES III population, data were adjusted for age by the direct method to match the 1980 U.S. population.16 Univariate t-statistics were calculated with use of a general linear-contrast procedure in SUDAAN15 so that we could examine age-adjusted or unadjusted differences in the seroprevalence of HCV between the highest and lowest levels of each variable, with a two-sided P value of less than 0.05 considered to indicate statistical significance.Backward stepwise logistic regression in SUDAAN was used to determine independent predictors of HCV infection in a multivariate model applied to persons 17 to 59 years old. Variables with a Satterthwaite-adjusted F-statistic at P<0.05 were considered significant and were allowed to remain in the model.15
Prevalence of Anti-HCV and Social and Demographic CharacteristicsOf the approximately 40,000 persons who were selected for inclusion in NHANES III, 30,930 were at least six years old; 25,733 of this group agreed to be interviewed, and 23,527 agreed to be examined. Of these 23,527 subjects, 21,241 (90 percent) were tested for anti-HCV. Rates of participation were lower for subjects 6 to 11 years old (84 percent) and more than 70 years old (82 percent). Rates of participation were no different when we compared persons who reported engaging in high-risk behavior with those who did not. The prevalence of anti-HCV was 1.8 percent (95 percent confidence interval, 1.5 to 2.3 percent), which corresponds to approximately 3.9 million people in the United States (95 percent confidence interval, 3.1 million to 4.8 million) who have been infected with HCV.The prevalence of HCV infection was higher among non-Hispanic blacks than among non-Hispanic whites and higher among male subjects than among female subjects (Table 1Table 1Prevalence of Antibody to HCV (Anti-HCV) According to Demographic Characteristics in NHANES III.). In all racial–ethnic groups, the prevalence of infection was low among subjects in the younger and older age groups (Table 2Table 2Prevalence of Antibody to HCV (Anti-HCV) According to Age and Race or Ethnic Group in NHANES III.), although among non-Hispanic blacks prevalence began to increase at an earlier age (12 to 19 years) than in the other groups. The delayed peak in prevalence among Mexican Americans 50 to 59 years old was probably attributable to the small numbers of subjects and may not accurately reflect the true prevalence in this group. Sixty-five percent of all anti-HCV–positive persons were 30 to 49 years old. The highest observed prevalence was 9.8 percent among black men who were 40 to 49 years old. A higher prevalence of HCV infection also was observed among subjects who were below the poverty level, subjects older than 16 years who were divorced or separated, and subjects who had completed 12 or fewer years of education (Table 1). No association was found between the prevalence of HCV infection and residence in a metropolitan area or in a particular geographic region, prior military service, or foreign birth (Table 1).
Risk Factors for HCV InfectionThe prevalence of HCV infection was not associated with employment in a health-related occupation (Table 3Table 3Age-Adjusted Prevalence of Antibodies to HCV (Anti-HCV) According to Race or Ethnic Group and Potential Risk Factors for Infection in NHANES III.), surgery that might have included blood transfusion (e.g., hysterectomy), or a higher frequency of dental visits (data not shown). An increased prevalence of infection was associated with a history of cocaine or marijuana use among all racial–ethnic groups, and prevalence increased with an increasing number of times each drug was used (Table 3). Approximately 14 percent of the participants 17 to 59 years old reported ever having used cocaine, with the highest frequency of use (22 percent) among 25-to-29-year-olds and 30-to-39-year-olds. Among those who had ever used cocaine, the prevalence of infection increased with age, reaching 18.8 percent among those 40 to 59 years old, although this age group reported the lowest frequency of use (6 percent). Forty-five percent of participants reported ever having smoked marijuana, and 12 percent reported smoking it 100 or more times. Although the prevalence of HCV infection among those who had smoked marijuana 100 or more times was similar among subjects in all age groups starting at 30 years (12.3 to 12.8 percent), the proportion who reported smoking marijuana 100 or more times was highest among 30-to-39-year-olds (19 percent) and declined after the age of 40 years.A higher prevalence of HCV infection was also associated with an early age at first sexual intercourse, a greater number of sexual partners, and infection with herpes simplex virus type 2 (Table 3). Twenty-eight percent of participants 17 to 59 years old reported having had 10 or more sexual partners, and 4 percent reported 50 or more. Although the highest prevalence of HCV infection among participants who reported having 10 or more sexual partners was found among persons 30 to 39 years old (7.4 percent), the proportion that reported having 10 or more partners was similar among persons in all age groups from 25 to 49 years of age (30 to 34 percent).Among participants of all ages, those with serologic evidence of HBV infection were more than six times as likely to be positive for HCV infection as participants without evidence of HBV infection (10.2 percent vs. 1.6 percent [P<0.001], after adjustment for age). Similarly, participants who were positive for HCV infection were nearly six times as likely to be positive for HBV infection as those who were negative for HCV infection (25.7 percent vs. 4.5 percent [P<0.001], after adjustment for age). The age-adjusted prevalence of coinfection with HBV and HCV increased with an increasing number of times cocaine or marijuana was used and with an increasing number of lifetime sexual partners.Using multivariate analysis, we found that the factors with the strongest independent associations with HCV infection among persons 17 to 59 years old were illegal drug use (ever having used cocaine or having smoked marijuana 100 or more times) and high-risk sexual behavior (an early age at first intercourse or 50 or more lifetime sexual partners) in the absence of illegal drug use (Table 4Table 4Relative Odds of Positivity for Antibodies to HCV among Subjects 17 to 59 Years Old, According to Selected Variables in NHANES III.). Marital status, income (above or below the poverty level), and the number of years of education also remained independently associated with infection, whereas race or ethnic group did not. No significant interactions were found between age and sex, race or ethnic group and sex, or illegal drug use and high-risk sexual behavior. Including an interaction term for age and race or ethnic group in the model had no effect on the adjusted odds ratios.
Prevalence of Viremia and Distribution of GenotypesThe prevalence of positivity for HCV RNA among anti-HCV–positive participants was 73.9 percent (95 percent confidence interval, 65.8 to 83.0 percent). This prevalence corresponds to an estimated 2.7 million persons (95 percent confidence interval, 2.4 million to 3.0 million) with chronic HCV infection nationwide. Non-Hispanic blacks were more likely to be HCV RNA–positive (86.2 percent; 95 percent confidence interval, 78.0 to 95.2 percent) than non-Hispanic whites (67.6 percent; 95 percent confidence interval, 56.1 to 81.6 percent) or Mexican Americans (73.6 percent; 95 percent confidence interval, 66.8 to 81.2 percent) (P=0.02 for both comparisons).Among subjects who were anti-HCV–positive, there was little variation in the prevalence of HCV RNA according to age among those who were at least 20 years old (weighted average, 75.6 percent; 95 percent confidence interval, 67.3 to 84.9 percent). Although this prevalence was 2.5 times as high as that among younger persons (weighted average, 30.1 percent; 95 percent confidence interval, 9.8 to 92.8 percent), the validity of this difference is questionable because of the small number of HCV RNA–positive persons less than 20 years old (four subjects), and the wide, unstable confidence interval. The only significant difference according to sex was among non-Hispanic blacks, of whom male subjects were more likely to be positive for HCV RNA than female subjects (97.8 percent vs. 70.2 percent, P=0.002). Genotype was determined for 250 of the 283 HCV RNA–positive samples (88.3 percent); 56.7 percent of the 250 samples were classified as 1a, 17.0 percent as 1b, 3.5 percent as 2a, 11.4 percent as 2b, 7.4 percent as 3a, 0.9 percent as 4, and 3.2 percent as 6.
DiscussionThe data from our national seroprevalence survey indicate that HCV infection is the most common chronic blood-borne infection in the United States. Our estimates of prevalence might be considered conservative. The NHANES III excluded incarcerated and homeless persons, groups that have high rates of HCV infection, and although the proportion of anti-HCV–positive persons found to have viremia was consistent with that observed in other studies,17-19 we tested only a single sample for each subject. Some HCV-infected persons are intermittently positive for HCV RNA,20 and a single negative result does not exclude the possibility of chronic infection. The predominance of genotype 1a among HCV-infected persons in our study may reflect the unselected nature of the population, as compared with populations of patients referred for evaluation and treatment in other studies.21In most cases, transmission of HCV had occurred in the recent past, primarily among young adults as a result of drug use and high-risk sexual behavior. The low prevalence of anti-HCV among older persons is most likely due to a cohort effect, with the risk of acquiring HCV infection lower in the distant past than in the recent past. The rates of antibody loss and death from liver disease among HCV-infected persons are reportedly low.17,20 The low prevalence of anti-HCV among persons less than 20 years old also reflects a low risk of infection, since the sensitivity of second-generation anti-HCV assays for detecting HCV infections is the same in infants, children, and adults.22,23Other studies have demonstrated that injection-drug use is the single most important risk factor for HCV infection.24-26 Because history of injection-drug use was not ascertained in the NHANES III, and because there is no biologically plausible mechanism to explain transmission through marijuana use, it has to be presumed that marijuana use serves as a surrogate for other methods of transmission (such as injection-drug use and high-risk sexual practices). In contrast, among persons who use cocaine, transmission could occur through sharing of blood-contaminated straws or other devices.18 However, intranasal cocaine use in the absence of injection-drug use has been very uncommon among patients with acute hepatitis C26; among injection-drug users with acute hepatitis C, most report also having used cocaine and marijuana (unpublished data). Although intranasal cocaine use could have contributed to the transmission of HCV, it is unlikely to explain the large number of infections associated with drug use in our study.The lack of a biologically plausible mechanism of transmission through marijuana use, the relation among age, seroprevalence, and patterns of cocaine use, and the direct correlation between coinfection with HBV and HCV and the frequency of drug use suggest that a substantial proportion of HCV-infected persons who reported the use of illegal drugs as defined in our study also had a history of injection-drug use. However, other risk factors, such as high-risk sexual activity or blood transfusion during treatment for traumatic injuries, might be associated with the use of drugs that are not injected and might account for an unidentified proportion of infections in this risk group.The proportion of HCV infections associated with high-risk sexual behavior was similar to that found for persons with acute hepatitis C.26 The dose–response relation between the prevalence of infection and increasing numbers of sexual partners, even after adjustment for illegal drug use, is consistent with the results of other studies.24,27-29 Although the spread of HCV through sexual activity might be inefficient, as demonstrated by the low infection rates among the spouses of persons with hepatitis C,30 the large number of chronically infected persons in the population provides numerous opportunities for exposure among persons who have multiple sexual partners.The NHANES III did not obtain information on transfusion history, and we cannot directly estimate the proportion of infections acquired by this route. The incidence of transfusion-associated hepatitis C was relatively high during the two or more decades before the NHANES III, and older persons were disproportionately affected.31-33 On the basis of the age-specific incidence of post-transfusion hepatitis during the 20 years before this study, the CDC estimates that transfusions might have been the source of infection for about 7 percent of the 3.9 million living persons who have been infected with HCV (unpublished data). This proportion is consistent with the low prevalence of HCV infection currently observed among older persons and with the results of studies of acute community-acquired non-A, non-B hepatitis, which indicated that less than 20 percent of cases were acquired through transfusions.20,24,25,34 Since 1990, HCV has rarely been transmitted by blood transfusion in the United States.Although occupational exposure, such as unintentional needle-stick injuries, can result in infection,30,35 health care workers in general appear not to be at increased risk for HCV infection,36-38 and they do not make up a substantial part of the HCV-infected population. The extent to which perinatal exposure contributes to HCV infection in the general population could not be measured by the NHANES III, but it is likely to be relatively low.Neither sex nor racial–ethnic group was associated with HCV infection independently of the sociodemographic and behavioral risk factors we studied. Low socioeconomic status might represent unidentified factors that enhance the opportunity for exposure to infected persons.In the United States, there is a large reservoir of HCV-infected persons who can transmit the infection to others and who are at risk for HCV-related chronic diseases. To prevent new infections, public health programs should focus on preventing the initiation of high-risk drug-related and sexual behavior and on providing risk-reduction counseling and services to those engaged in high-risk activities.30 In addition, we need to develop more effective therapies for persons with infection,39,40 particularly for those with genotype 1 — the most common genotype in the United States and the most difficult to treat — as well as approaches to the treatment of current or former injection-drug users. Most HCV-infected persons are younger than 50 years of age. As a result, the burden of disease associated with HCV infection is likely to increase during the next 10 to 20 years as this cohort reaches the age at which complications of chronic liver disease typically occur. The frequency of such complications might be reduced if infected persons were identified and provided with counseling and appropriate medical care.30,41Preliminary results of this study were presented at the Ninth Triennial International Symposium on Viral Hepatitis and Liver Disease, Rome, April 21–25, 1996.We are indebted to Stephen Lambert and Mar Than for their assistance with serologic testing..
Source InformationFrom the Hepatitis Branch, Division of Viral and Rickettsial Diseases, National Center for Infectious Diseases, Centers for Disease Control and Prevention, Atlanta (M.J.A., O.V.N., F.G., L.A.M., H.S.M.); the National Center for Health Statistics, Centers for Disease Control and Prevention, Hyattsville, Md. (D.K.-M., G.M.M.); and the National Institute of Allergy and Infectious Diseases, Bethesda, Md. (R.A.K.).Address reprint requests to Dr. Alter at the Hepatitis Branch, Mailstop G37, Centers for Disease Control and Prevention, Atlanta, GA 30333.
- .
- 1.
Choo QL, Kuo G, Weiner AJ, Overby LR, Bradley DW, Houghton M. Isolation of a cDNA clone derived from a blood-borne non-A, non-B viral hepatitis genome. Science 1989;244:359-362
CrossRef | Web of Science | Medline
- 2.
Kuo G, Choo QL, Alter HJ, et al. An assay for circulating antibodies to a major etiologic virus of human non-A, non-B hepatitis. Science 1989;244:362-364
CrossRef | Web of Science | Medline
- 3.
Alter MJ. Epidemiology of hepatitis C in the West. Semin Liver Dis 1995;15:5-14
CrossRef | Web of Science | Medline
- 4.
Mansell CJ, Locarnini SA. Epidemiology of hepatitis C in the East. Semin Liver Dis 1995;15:15-32
CrossRef | Web of Science | Medline
- 5National Center for Health Statistics. Plan and operation of the Third National Health and Nutrition Examination Survey, 1988–94. Vital and health statistics. Series 1. No. 32. Washington, D.C.: Government Printing Office, July 1994. (DHHS publication no. (PHS) 94-1308.).
- 6.
Nainan OV, Cromeans TL, Margolis HS. Sequence-specific, single primer amplification and detection of PCR products for identification of hepatitis viruses. J Virol Methods 1996;61:127-134
CrossRef | Web of Science | Medline
- 7.
Simmonds P, Holmes EC, Cha TA, et al. Classification of hepatitis C virus into six major genotypes and a series of subtypes by phylogenetic analysis of the NS-5 region. J Gen Virol 1993;74:2391-2399
CrossRef | Web of Science | Medline
- 8.
Devereux J, Haeberli P, Smithies O. A comprehensive set of sequence analysis programs for the VAX. Nucleic Acids Res 1983;12:387-395
CrossRef | Web of Science
- 9.
McQuillan GM, Coleman PJ, Kurszon-Moran D, Moyer LA, Lambert SB, Margolis HS. Prevalence of hepatitis B virus infection in the United States: the National Health and Nutrition Examination Surveys, 1976 through 1994. Am J Public Health 1999;89:14-18
Web of Science | Medline
- 10.
Lee FK, Coleman RM, Pereira L, Bailey PD, Tatsuno M, Nahmias A. Detection of herpes simplex virus type 2-specific antibody with glycoprotein G. J Clin Microbiol 1985;22:641-644
Web of Science | Medline
- 11.
Coleman RM, Pereira L, Bailey PD, Dondero D, Wickliffe C, Nahmias A. Determination of herpes simplex virus type-specific antibodies by enzyme-linked immunosorbent assay. J Clin Microbiol 1983;18:287-291
Web of Science | Medline
- 12.
Mosley JW, Goodwin RF. Stability of serum-glutamic pyruvic transaminase activity on storage. Tech Bull Regist Med Technol 1965;35:183-187
- 13Mohadjer L, Montaquila J, Waksberg J, et al. National Health and Nutrition Examination Survey III: weighting and examination methodology. Hyattsville, Md.: National Center for Health Statistics, February 1996..
- 14Ezzati T, Khare M. Nonresponse adjustments in a national health survey. In: 1992 Proceedings of the Section on Survey Research Methods. Alexandria, Va.: American Statistical Association, 1993:339-44..
- 15Shah BV, Barnwell BG, Hurt PN, La Vange LM. SUDAAN users manual, release 5.30. Research Triangle Park, N.C.: Research Triangle Institute, 1991..
- 16Kahn HA, Sempos CT. Statistical methods in epidemiology. New York: Oxford University Press, 1989..
- 17.
Seeff LB, Buskell-Bales Z, Wright EC, et al. Long-term mortality after transfusion-associated non-A, non-B hepatitis. N Engl J Med 1992;327:1906-1911
Full Text | Web of Science | Medline
- 18.
Conry-Cantilena C, VanRaden M, Gibble J, et al. Routes of infection, viremia, and liver disease in blood donors found to have hepatitis C virus infection. N Engl J Med 1996;334:1691-1696
Full Text | Web of Science | Medline
- 19.
Esteban JI, Lopez-Talavera JC, Genesca J, et al. High rate of infectivity and liver disease in blood donors with antibodies to hepatitis C virus. Ann Intern Med 1991;115:443-449
Web of Science | Medline
- 20.
Alter MJ, Margolis HS, Krawczynski K, et al. The natural history of community-acquired hepatitis C in the United States. N Engl J Med 1992;327:1899-1905
Full Text | Web of Science | Medline
- 21.
Lau JY, Mizokami M, Kolberg JA, et al. Application of six hepatitis C virus genotyping systems to sera from chronic hepatitis C patients in the United States. J Infect Dis 1995;171:281-289
CrossRef | Web of Science | Medline
- 22.
Mast EE, Alter MJ. Hepatitis C. Semin Pediatr Infect Dis 1997;8:17-22
- 23.
Thomas SL, Newell ML, Peckham CS, Ades AE, Hall AJ. Use of polymerase chain reaction and antibody tests in the diagnosis of vertically transmitted hepatitis C virus infection. Eur J Clin Microbiol Infect Dis 1997;16:711-719
CrossRef | Web of Science | Medline
- 24.
Alter MJ, Gerety RJ, Smallwood LA, et al. Sporadic non-A, non-B hepatitis: frequency and epidemiology in an urban U.S. population. J Infect Dis 1982;145:886-893
CrossRef | Web of Science | Medline
- 25.
Alter MJ, Hadler SC, Judson FN, et al. Risk factors for acute non-A, non-B hepatitis in the United States and association with hepatitis C virus infection. JAMA 1990;264:2231-2235
CrossRef | Web of Science | Medline
- 26.
Alter MJ. Epidemiology of hepatitis C. Hepatology 1997;26:Suppl 1:62S-65S
CrossRef | Web of Science | Medline
- 27.
Thomas DL, Cannon RO, Shapiro CN, Hook EW III, Alter MJ, Quinn TC. Hepatitis C, hepatitis B, and human immunodeficiency virus infections among non-intravenous drug-using patients attending clinics for sexually transmitted diseases. J Infect Dis 1994;169:990-995
CrossRef | Web of Science | Medline
- 28.
Thomas DL, Zenilman JM, Alter HJ, et al. Sexual transmission of hepatitis C virus among patients attending Baltimore sexually transmitted diseases clinics -- an analysis of 309 sex partnerships. J Infect Dis 1995;171:768-775
CrossRef | Web of Science | Medline
- 29.
Alter MJ, Coleman PJ, Alexander WJ, et al. Importance of heterosexual activity in the transmission of hepatitis B and non-A, non-B hepatitis. JAMA 1989;262:1201-1205
CrossRef | Web of Science | Medline
- 30Recommendations for prevention and control of hepatitis C virus (HCV) infection and HCV-related chronic diseaseMMWR Morb Mortal Wkly Rep 1998;47:1-39.
- 31.
Alter HJ, Holland PV, Purcell RH, et al. Posttransfusion hepatitis after exclusion of commercial and hepatitis-B antigen-positive donors. Ann Intern Med 1972;77:691-699
Web of Science | Medline
- 32.
Seeff LB, Wright EC, Zimmerman HJ, McCollum RW. VA cooperative study of post-transfusion hepatitis, 1969-1974: incidence and characteristics of hepatitis and responsible risk factors. Am J Med Sci 1975;270:355-362
CrossRef | Web of Science | Medline
- 33.
Vamvakas EC, Taswell HF. Epidemiology of blood transfusion. Transfusion 1994;34:464-470
CrossRef | Web of Science | Medline
- 34.
Francis DP, Hadler SC, Prendergast TJ, et al. Occurrence of hepatitis A, B, and non-A/non-B in the United States: CDC Sentinel County Hepatitis Study I. Am J Med 1984;76:69-74
CrossRef | Web of Science | Medline
- 35.
Lanphear BP, Linnemann CC Jr, Cannon CG, DeRonde MM, Pendy L, Kerley LM. Hepatitis C virus infection in healthcare workers: risk of exposure and infection. Infect Control Hosp Epidemiol 1994;15:745-750
CrossRef | Web of Science | Medline
- 36.
Thomas DL, Factor SH, Kelen GD, Washington AS, Taylor E Jr, Quinn TC. Viral hepatitis in health care personnel at the Johns Hopkins Hospital: the seroprevalence of and risk factors for hepatitis B virus and hepatitis C virus infection. Arch Intern Med 1993;153:1705-1712
CrossRef | Web of Science | Medline
- 37.
Panlilio AL, Shapiro CN, Schable CA, et al. Serosurvey of human immunodeficiency virus, hepatitis B virus, and hepatitis C virus infection among hospital-based surgeons. J Am Coll Surg 1995;180:16-24
Web of Science | Medline
- 38Shapiro CN, Tokars JI, Chamberland ME, American Academy of Orthopaedic Surgeons Serosurvey Study Committee. Use of hepatitis-B vaccine and infection with hepatitis B and C among orthopaedic surgeons.J Bone Joint Surg Am 1996;78:1791-800..
- 39.
McHutchison JG, Gordon SC, Schiff ER, et al. Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. N Engl J Med 1998;339:1485-1492
Full Text | Web of Science | Medline
- 40.
Davis GL, Esteban-Mur R, Rustgi V, et al. Interferon alfa-2b alone or in combination with ribavirin for the treatment of relapse of chronic hepatitis C. N Engl J Med 1998;339:1493-1499
Full Text | Web of Science | Medline
- 41.
. Hepatology 1997;26:25-105 National Institutes of Health Consensus Development Conference Panel statement: management of hepatitis C
CrossRef | Web of Science
Citing Articles
- 1Christophe Moreno, Thomas Berg, Tawesak Tanwandee, Satawat Thongsawat, Hans Van Vlierberghe, Stefan Zeuzem, Oliver Lenz, Monika Peeters, Vanitha Sekar, Goedele De Smedt. (2012) Antiviral activity of TMC435 monotherapy in patients infected with HCV genotypes 2–6: TMC435-C202, a phase IIa, open-label study. Journal of Hepatology 56:6, 1247-1253.
- 2Maxine M. Denniston, R. Monina Klevens, Geraldine M. McQuillan, Ruth B. Jiles. (2012) Awareness of infection, knowledge of hepatitis C, and medical follow-up among individuals testing positive for hepatitis C: National Health and Nutrition Examination Survey 2001-2008. Hepatology 55:6, 1652-1661.
- 3Yasuteru Kondo, Yoshiyuki Ueno, Masashi Ninomiya, Keiichi Tamai, Yasuhito Tanaka, Jun Inoue, Eiji Kakazu, Koju Kobayashi, Osamu Kimura, Masahito Miura, Takeshi Yamamoto, Tomoo Kobayashi, Takehiko Igarashi, Tooru Shimosegawa. (2012) Sequential immunological analysis of HBV/HCV co-infected patients during Peg-IFN/RBV therapy. Journal of Gastroenterology.
- 4Kyoko Okada, Norihiro Furusyo, Eiichi Ogawa, Hiroaki Ikezaki, Tsuyoshi Ihara, Takeo Hayashi, Mosaburo Kainuma, Masayuki Murata, Jun Hayashi. (2012) Association between chronic hepatitis C virus infection and high levels of circulating N-terminal pro-brain natriuretic peptide. Endocrine.
- 5Arjmand R. Mufti, Nancy Reau. (2012) Liver Disease in Pregnancy. Clinics in Liver Disease 16:2, 247-269.
- 6Westyn Branch-Elliman, Don Weiss, Sharon Balter, Katherine Bornschlegel, Michael Phillips. (2012) Hepatitis C transmission due to contamination of multidose medication vials: Summary of an outbreak and a call to action. American Journal of Infection Control.
- 7Helen S Yee, Michael F Chang, Christine Pocha, Joseph Lim, David Ross, Timothy R Morgan, Alexander Monto. (2012) Update on the Management and Treatment of Hepatitis C Virus Infection: Recommendations from the Department of Veterans Affairs Hepatitis C Resource Center Program and the National Hepatitis C Program Office. The American Journal of Gastroenterology.
- 8Karla J Helbig, Michael R Beard. (2012) The interferon signaling pathway genes as biomarkers of hepatitis C virus disease progression and response to treatment. Biomarkers in Medicine 6:2, 141-150.
- 9Danielle Scher, Enes Kanlic, Julia Bader, Melchor Ortiz, Amr Abdelgawad. (2012) Hepatitis C Viral Infection as an Associated Risk Factor for Necrotizing Fasciitis. Orthopedics 35:4, e510-e513.
- 10Shimian Zou, Susan L. Stramer, Roger Y. Dodd. (2012) Donor Testing and Risk: Current Prevalence, Incidence, and Residual Risk of Transfusion-Transmissible Agents in US Allogeneic Donations. Transfusion Medicine Reviews 26:2, 119-128.
- 11Erik J. Groessl, Lin Liu, Samuel B. Ho, Fasiha Kanwal, Allen L. Gifford, Steven M. Asch. (2012) National patterns and predictors of liver biopsy use for management of hepatitis C. Journal of Hepatology.
- 12K. Hermanstyne, D. R. Bangsberg, K. Hennessey, C. Weinbaum, J. A. Hahn. (2012) The association between use of non-injection drug implements and hepatitis C virus antibody status in homeless and marginally housed persons in San Francisco. Journal of Public Health.
- 13Z.A. Randriamanantany, D.H. Rajaonatahina, F.É. Razafimanantsoa, M.T. Rasamindrakotroka, R. Andriamahenina, F.B. Rasoarilalaomanarivo, S.P. Hanitriniala, F.R. Herisoa, O.A. Rakoto-Alson, A. Rasamindrakotroka. (2012) Prevalence and trends of hepatitis C virus among blood donors in Antananarivo, from 2003 to 2009. Transfusion Clinique et Biologique.
- 14Kevin X. Chen, Charles A. Lesburg, Bancha Vibulbhan, Weiying Yang, Tin-Yau Chan, Srikanth Venkatraman, Francisco Velazquez, Qingbei Zeng, Frank Bennett, Gopinadhan N. Anilkumar, Jose Duca, Yueheng Jiang, Patrick Pinto, Li Wang, Yuhua Huang, Oleg Selyutin, Stephen Gavalas, Haiyan Pu, Sony Agrawal, Boris Feld, Hsueh-Cheng Huang, Cheng Li, Kuo-Chi Cheng, Neng-Yang Shih, Joseph A. Kozlowski, Stuart B. Rosenblum, F. George Njoroge. (2012) A Novel Class of Highly Potent Irreversible Hepatitis C Virus NS5B Polymerase Inhibitors. Journal of Medicinal Chemistry120222085506007.
- 15Bruce R. Bacon, Omer Khalid. (2012) Triple therapy with boceprevir for HCV genotype 1 infection: phase III results in relapsers and nonresponders. Liver International 32, 51-53.
- 16A. Chris Krueger, Darold L. Madigan, David W. Beno, David A. Betebenner, Robert Carrick, Brian E. Green, Wenping He, Dachun Liu, Clarence J. Maring, Keith F. McDaniel, Hongmei Mo, Akhteruzzaman Molla, Christopher E. Motter, Tami J. Pilot-Matias, Michael D. Tufano, Dale J. Kempf. (2012) Novel Hepatitis C virus replicon inhibitors: Synthesis and structure–activity relationships of fused pyrimidine derivatives. Bioorganic & Medicinal Chemistry Letters.
- 17E. Delwart, E. Slikas, S. L. Stramer, H. Kamel, D. Kessler, D. Krysztof, L. H. Tobler, D. M. Carrick, W. Steele, D. Todd, D. J. Wright, S. H. Kleinman, M. P. Busch, . (2012) Genetic Diversity of Recently Acquired and Prevalent HIV, Hepatitis B Virus, and Hepatitis C Virus Infections in US Blood Donors. Journal of Infectious Diseases.
- 18Timothy T. Gordon-Walker, John P. Iredale. 2012. Abnormal Liver Function Tests: Diagnostic Approach. , 144-161..
- 19S. Ramia, N. M. Melhem, K. Kreidieh. (2012) Hepatitis C virus infection in the Middle East and North Africa "MENA" region: injecting drug users (IDUs) is an under-investigated population. Infection.
- 20Kevin X. Chen, Bancha Vibulbhan, Weiying Yang, Mousumi Sannigrahi, Francisco Velazquez, Tin-Yau Chan, Srikanth Venkatraman, Gopinadhan N. Anilkumar, Qingbei Zeng, Frank Bennet, Yueheng Jiang, Charles A. Lesburg, Jose Duca, Patrick Pinto, Stephen Gavalas, Yuhua Huang, Wanli Wu, Oleg Selyutin, Sony Agrawal, Boris Feld, Hsueh-Cheng Huang, Cheng Li, Kuo-Chi Cheng, Neng-Yang Shih, Joseph A. Kozlowski, Stuart B. Rosenblum, F. George Njoroge. (2012) Structure–Activity Relationship (SAR) Development and Discovery of Potent Indole-Based Inhibitors of the Hepatitis C Virus (HCV) NS5B Polymerase. Journal of Medicinal Chemistry120106152720008.
- 21Handan Wand, Rebecca Guy, Matthew Law, David P. Wilson, Lisa Maher. (2012) High Rates of Late HIV Diagnosis Among People Who Inject Drugs Compared to Men Who Have Sex with Men and Heterosexual Men and Women in Australia. AIDS and Behavior.
- 22Anthony D. Martinez, Robert G. Gish. (2012) HCV In At Risk Populations: Who Can be Treated and How?. Current Hepatitis Reports.
- 23Hans L. Tillmann, John G. McHutchison. 2012. Hepatitis C. , 564-598..
- 24Jennifer E. Layden, Scott J. Cotler, Shellee A. Grim, Michael J. Fischer, Michael R. Lucey, Nina M. Clark. (2012) Impact of Donor and Recipient Race on Survival After Hepatitis C-Related Liver Transplantation. Transplantation1.
- 25Alexander Ploss, Matthew J Evans. (2012) Hepatitis C virus host cell entry. Current Opinion in Virology.
- 26Yasuteru Kondo, Yoshiyuki Ueno, Tooru Shimosegawa. (2012) Biological Significance of HCV in Various Kinds of Lymphoid Cells. International Journal of Microbiology 2012, 1-7.
- 27Seth Bradford, J. A. Cowan. (2012) Catalytic metallodrugs targeting HCV IRES RNA. Chemical Communications.
- 28Elizabeth C. Verna, Rosa Valadao, Erica Farrand, Elsa M. Pichardo, Jennifer C. Lai, Norah A. Terrault, Robert S. Brown. (2012) The effects of ethnicity and socioeconomic status on survival and severity of fibrosis in liver transplant recipients with hepatitis C virus. Liver Transplantationn/a-n/a.
- 29F. M. Aslinia, S. K. Wasan, A. L. Mindikoglu, O. A. Adeyemo, B. Philosophe, C. Drachenberg, C. D. Howell. (2012) End-stage renal disease and African American race are independent predictors of mild liver fibrosis in patients with chronic hepatitis C infection. Journal of Viral Hepatitisno-no.
- 30Lisa J. McGarry, Vivek S. Pawar, Hemangi R. Panchmatia, Jaime L. Rubin, Gary L. Davis, Zobair M. Younossi, James C. Capretta, Michael J. O'Grady, Milton C. Weinstein. (2012) Economic model of a birth cohort screening program for hepatitis C virus. Hepatologyn/a-n/a.
- 31Deok Ja Oh, Yoon Mee Park, Young Ik Seo, Jae Sook Lee, Ja Young Lee. (2012) Prevalence of Hepatitis C Virus Infections and Distribution of Hepatitis C Virus Genotypes among Korean Blood Donors. Annals of Laboratory Medicine 32:3, 210.
- 32Anita Arora, Natalia Mendoza, Stephen K. Tyring. 2011. Antiviral Market Overview. ..
- 33Jama M. Darling, Stanley M. Lemon, Michael W. Fried. 2011. Hepatitis C. , 582-652..
- 34Carla Venturi, Javier Bueno, Lluís Castells, Jesus Quintero, Isabel Casas, Helena Allende, Vicente Martinez-Ibañez, Ramón Charco. (2011) Long-term outcome of hepatitis C virus infections acquired after pediatric liver transplantation. Liver Transplantation 17:12, 1474-1480.
- 35Ajay R. Bharti, Scott L. Letendre, Tanya Wolfson, David Clifford, Ann C. Collier, Benjamin Gelman, Justin McArthur, Christina Marra, Allen McCutchan, Susan Morgello, David Simpson, Ron J. Ellis, Igor Grant. (2011) Clinical variables identify seronegative HCV co-infection in HIV-infected individuals. Journal of Clinical Virology 52:4, 328-332.
- 36Basmattee Boodram, Ronald C. Hershow, Scott J. Cotler, Lawrence J. Ouellet. (2011) Chronic hepatitis C virus infection and increases in viral load in a prospective cohort of young, HIV-uninfected injection drug users. Drug and Alcohol Dependence 119:3, 166-171.
- 37Xu Wang, Ting Zhang, Wen-Zhe Ho. (2011) Opioids and HIV/HCV Infection. Journal of Neuroimmune Pharmacology 6:4, 477-489.
- 38Alla Kachko, Galina Kochneva, Galina Sivolobova, Antonina Grazhdantseva, Tatyana Lupan, Iryna Zubkova, Frances Wells, Michael Merchlinsky, Ollie Williams, Hisayoshi Watanabe, Alla Ivanova, Aleksander Shvalov, Valeriy Loktev, Sergei Netesov, Marian E. Major. (2011) New neutralizing antibody epitopes in hepatitis C virus envelope glycoproteins are revealed by dissecting peptide recognition profiles. Vaccine 30:1, 69-77.
- 39Anthony F. Porto, Lauren Tormey, Joseph K. Lim. (2011) Management of chronic hepatitis C infection in children. Current Opinion in Pediatrics1.
- 40Hussein H. Aly, Kunitada Shimotohno, Makoto Hijikata, Tsukasa Seya. (2011) In vitro models for the analysis of HCV life cycle. Microbiology and Immunologyno-no.
- 41Omer Khalid, Bruce R Bacon. (2011) Boceprevir in the treatment of hepatitis C infection: rationale and clinical data. Clinical Investigation 1:12, 1717-1729.
- 42Kathleen B. Schwarz. 2011. HCV and the Pediatric Population. , 190-195..
- 43Yolanda R. Davila, Elizabeth Reifsnider, Irma Pecina. (2011) Familismo: influence on Hispanic health behaviors. Applied Nursing Research 24:4, e67-e72.
- 44Peter A. Hevezi, Edward Tom, Keith Wilson, Peter Lambert, Gabriela Gutierrez-Reyes, David Kershenobich, Albert Zlotnik. (2011) Gene expression patterns in livers of Hispanic patients infected with hepatitis C virus. Autoimmunity 44:7, 532-542.
- 45Donna M. Evon, Denise A. Esserman, Darmendra Ramcharran, Jason E. Bonner, Michael W. Fried. (2011) Social support and clinical outcomes during antiviral therapy for chronic hepatitis C. Journal of Psychosomatic Research 71:5, 349-356.
- 46K. A. Forde, K. Haynes, A. B. Troxel, S. Trooskin, M. T. Osterman, S. E. Kimmel, J. D. Lewis, V. Lo Re. (2011) Risk of myocardial infarction associated with chronic hepatitis C virus infection: a population-based cohort study*. Journal of Viral Hepatitisno-no.
- 47Hamisu M. Salihu, Laura Connell, Jason L. Salemi, Euna M. August, Hanna E. Weldeselasse, Amina P. Alio. (2011) Prevalence and Temporal Trends of Hepatitis B, Hepatitis C, and HIV/AIDS Co-infection During Pregnancy Across the Decade, 1998–2007. Journal of Women's Health111019074632004.
- 48Donna M Evon, Kelly Simpson, Scott Kixmiller, Joseph Galanko, Karen Dougherty, Carol Golin, Michael W Fried. (2011) A Randomized Controlled Trial of an Integrated Care Intervention to Increase Eligibility for Chronic Hepatitis C Treatment. The American Journal of Gastroenterology 106:10, 1777-1786.
- 49Benjamin Terrier, Fabrice Carrat, Guillaume Geri, Stanislas Pol, Lionel Piroth, Philippe Halfon, Thierry Poynard, Jean-Claude Souberbielle, Patrice Cacoub. (2011) Low 25-OH vitamin D serum levels correlate with severe fibrosis in HIV-HCV co-infected patients with chronic hepatitis. Journal of Hepatology 55:4, 756-761.
- 50Andres F. Carrion, Ravi Ghanta, Olveen Carrasquillo, Paul Martin. (2011) Chronic Liver Disease in the Hispanic Population of the United States. Clinical Gastroenterology and Hepatology 9:10, 834-841.
- 51Weihua Wang, Jianguo Lin, De Tan, Yanjuan Xu, Elizabeth M. Brunt, Xiaofeng Fan, Adrian M. Di Bisceglie. (2011) Divergent quasispecies evolution in de novo hepatitis C virus infection associated with bone marrow transplantation. Biochemical and Biophysical Research Communications 414:1, 148-152.
- 52Joerg-Patrick Stübgen. (2011) Immune-mediated myelitis associated with Hepatitis virus infections. Journal of Neuroimmunology 239:1-2, 21-27.
- 53Gopinadhan N. Anilkumar, Oleg Selyutin, Stuart B. Rosenblum, Qingbei Zeng, Yueheng Jiang, Tin-Yau Chan, Haiyan Pu, Li Wang, Frank Bennett, Kevin X. Chen, Charles A. Lesburg, Jose Duca, Stephen Gavalas, Yuhua Huang, Patrick Pinto, Mousumi Sannigrahi, Francisco Velazquez, Srikanth Venkatraman, Bancha Vibulbhan, Sony Agrawal, Eric Ferrari, Chuan-kui Jiang, H.-C. Huang, Neng-Yang Shih, F. George Njoroge, Joseph A. Kozlowski. (2011) II. Novel HCV NS5B polymerase inhibitors: Discovery of indole C2 acyl sulfonamides. Bioorganic & Medicinal Chemistry Letters.
- 54Gopinadhan N. Anilkumar, Charles A. Lesburg, Oleg Selyutin, Stuart B. Rosenblum, Qingbei Zeng, Yueheng Jiang, Tin-Yau Chan, Haiyan Pu, Henry Vaccaro, Li Wang, Frank Bennett, Kevin X. Chen, Jose Duca, Stephen Gavalas, Yuhua Huang, Patrick Pinto, Mousumi Sannigrahi, Francisco Velazquez, Srikanth Venkatraman, Bancha Vibulbhan, Sony Agrawal, Nancy Butkiewicz, Boris Feld, Eric Ferrari, Zhiqing He, Chuan-kui Jiang, Robert E. Palermo, Patricia Mcmonagle, H.-C. Huang, Neng-Yang Shih, George Njoroge, Joseph A. Kozlowski. (2011) I. Novel HCV NS5B polymerase inhibitors: Discovery of indole 2-carboxylic acids with C3-heterocycles. Bioorganic & Medicinal Chemistry Letters 21:18, 5336-5341.
- 55Ghina Ghazeeri, Lina Abdullah, Ossama Abbas. (2011) Immunological Differences in Women Compared with Men: Overview and Contributing Factors. American Journal of Reproductive Immunology 66:3, 163-169.
- 56Eric Chak, Andrew H. Talal, Kenneth E. Sherman, Eugene R. Schiff, Sammy Saab. (2011) Hepatitis C virus infection in USA: an estimate of true prevalence. Liver International 31:8, 1090-1101.
- 57Choongho Lee. (2011) Discovery of hepatitis C virus NS5A inhibitors as a new class of anti-HCV therapy. Archives of Pharmacal Research 34:9, 1403-1407.
- 58Omer Khalid, Bruce R. Bacon. (2011) Management of the Treatment-Experienced Patient Infected with Hepatitis C Virus Genotype 1: Options and Considerations. Clinics in Liver Disease 15:3, 573-583.
- 59Elisabetta Cariani, Erica Villa, Cristina Rota, Rosina Critelli, Tommaso Trenti. (2011) Translating pharmacogenetics into clinical practice: interleukin (IL)28B and inosine triphosphatase (ITPA) polymophisms in hepatitis C virus (HCV) infection. Clinical Chemistry and Laboratory Medicine 49:8, 1247-1256.
- 60X. Q. Lao, A. Thompson, J. G. McHutchison, J. J. McCarthy. (2011) Sex and age differences in lipid response to chronic infection with the hepatitis C virus in the United States National Health and Nutrition Examination Surveys. Journal of Viral Hepatitis 18:8, 571-579.
- 61Debasis Das, Jian Hong, Shu-Hui Chen, Guangyi Wang, Leonid Beigelman, Scott D. Seiwert, Brad O. Buckman. (2011) Recent advances in drug discovery of benzothiadiazine and related analogs as HCV NS5B polymerase inhibitors. Bioorganic & Medicinal Chemistry 19:16, 4690-4703.
- 62Archita P. Desai, Nancy Reau. (2011) Naives, Nonresponders, Relapsers: Who Is There Left to Treat?. Clinics in Liver Disease 15:3, 483-495.
- 63Shahriar Tavakoli-Tabasi, Ameena Bagree. (2011) A Longitudinal Cohort Study of Mucocutaneous Drug Eruptions During Interferon and Ribavirin Treatment of Hepatitis C. Journal of Clinical Gastroenterology1.
- 64S. S. El-Kamary, R. Jhaveri, M. D. Shardell. (2011) All-Cause, Liver-Related, and Non-Liver-Related Mortality Among HCV-Infected Individuals in the General US Population. Clinical Infectious Diseases 53:2, 150-157.
- 65Sanjay Kulkarni, Tamar H. Taddei. (2011) When should a hepatitis C-positive ESRD patient receive a renal transplant?. Seminars in Dialysis 24:4, 438-439.
- 66Jong Yeop Kim, Ji Eon Won, Sook-Hyang Jeong, Sang Jong Park, Seong Gyu Hwang, Sook-Kyoung Kang, Si Hyun Bae, Young Seok Kim, Han Chu Lee. (2011) Acute hepatitis C in Korea: Different modes of infection, high rate of spontaneous recovery, and low rate of seroconversion. Journal of Medical Virology 83:7, 1195-1202.
- 67B. P. Linas, B. Wang, M. Smurzynski, E. Losina, R. J. Bosch, B. R. Schackman, J. Rong, P. E. Sax, R. P. Walensky, J. Schouten, K. A. Freedberg. (2011) The impact of HIV/HCV co-infection on health care utilization and disability: results of the ACTG Longitudinal Linked Randomized Trials (ALLRT) Cohort. Journal of Viral Hepatitis 18:7, 506-512.
- 68W. N. Southern, M.-L. Drainoni, B. D. Smith, C. L. Christiansen, D. McKee, A. L. Gifford, C. M. Weinbaum, D. Thompson, E. Koppelman, S. Maher, A. H. Litwin. (2011) Hepatitis C testing practices and prevalence in a high-risk urban ambulatory care setting. Journal of Viral Hepatitis 18:7, 474-481.
- 69Valentina Santi, Daniela Buccione, Antonio Di Micoli, Gianluca Fatti, Marta Frigerio, Fabio Farinati, Paolo Del Poggio, Gianludovico Rapaccini, Maria Anna Di Nolfo, Luisa Benvegnù, Marco Zoli, Franco Borzio, Edoardo Giovanni Giannini, Eugenio Caturelli, Maria Chiaramonte, Mauro Bernardi, Franco Trevisani. (2011) The changing scenario of hepatocellular carcinoma over the last two decades in Italy. Journal of Hepatology.
- 70Zack S. Moore, Melissa K. Schaefer, Karen K. Hoffmann, Susan C. Thompson, Guo-Liang Xia, Yulin Lin, Yury Khudyakov, Jean-Marie Maillard, Jeffrey P. Engel, Joseph F. Perz, Priti R. Patel, Nicola D. Thompson. (2011) Transmission of Hepatitis C Virus During Myocardial Perfusion Imaging in an Outpatient Clinic. The American Journal of Cardiology 108:1, 126-132.
- 71R. J. Harris, M. Ramsay, V. D. Hope, L. Brant, M. Hickman, G. R. Foster, D. De Angelis. (2011) Hepatitis C prevalence in England remains low and varies by ethnicity: an updated evidence synthesis. The European Journal of Public Health.
- 72Rosen, Hugo R., . (2011) Chronic Hepatitis C Infection. New England Journal of Medicine 364:25, 2429-2438.
Full Text
- 73Randy W. Jackson, Matthew G. LaPorte, Torsten Herbertz, Tandy L. Draper, Janet A. Gaboury, Susan R. Rippin, Ravi Patel, Srinivas K. Chunduru, Christopher A. Benetatos, Dorothy C. Young, Christopher J. Burns, Stephen M. Condon. (2011) The discovery and structure–activity relationships of pyrano[3,4-b]indole-based inhibitors of hepatitis C virus NS5B polymerase. Bioorganic & Medicinal Chemistry Letters 21:11, 3227-3231.
- 74Julio Granados-Montiel, Joaquin Zúñiga, Jose Azocar, Edmond J. Feris, Daniel Terreros, Charles E. Larsen, Olga P. Clavijo, Alfredo Cruz-Lagunas, Derek Middleton, Chester A. Alper, Janardan P. Pandey, Edmond J. Yunis. (2011) Interaction between immunoglobulin allotypes and NK receptor genes in diabetes post-hepatitis C virus infection. Immunobiology 216:6, 686-691.
- 75Donna L. White, Peter A. Richardson, Mukhtar Al-Saadi, Stephanie J. Fitzgerald, Linda Green, Chami Amaratunge, Manvir Anand, Hashem B. El-Serag. (2011) Dietary History and Physical Activity and Risk of Advanced Liver Disease in Veterans with Chronic Hepatitis C Infection. Digestive Diseases and Sciences 56:6, 1835-1847.
- 76Tommaso Stroffolini, Franco Trevisani, Giovanbattista Pinzello, Franco Brunello, Maurizio A. Tommasini, Massimo Iavarone, Vito Di Marco, Fabio Farinati, Paolo Del Poggio, Franco Borzio, Mauro Borzio, Eugenio Caturelli, Maria Anna Di Nolfo, Marta Frigerio, Giuseppina Brancaccio, Giovanni Battista Gaeta. (2011) Changing aetiological factors of hepatocellular carcinoma and their potential impact on the effectiveness of surveillance. Digestive and Liver Disease.
- 77Fred M. Wu, Chinweike Ukomadu, Robert D. Odze, Anne Marie Valente, John E. Mayer Jr., Michael G. Earing. (2011) Liver Disease in the Patient with Fontan Circulation. Congenital Heart Disease 6:3, 190-201.
- 78Nagaraju Sarabu, Geetha Maddukuri, Devaraj Munikrishnappa, Kevin J. Martin, Rizwan A. Qazi, Alejandro Alvarez, Paul G. Schmitz. (2011) Safety and Efficacy of Transjugular Renal Biopsy Performed by Interventional Nephrologists. Seminars in Dialysis 24:3, 343-348.
- 79E. J. Groessl, K. R. Weingart, C. J. Stepnowsky, A. L. Gifford, S. M. Asch, S. B. Ho. (2011) The hepatitis C self-management programme: a randomized controlled trial. Journal of Viral Hepatitis 18:5, 358-368.
- 80Julie Samantray, Suchitra Zambare, Berhane Seyoum, Abdul B. Abou-Samra. (2011) Glucose Control and Lipid Metabolism in African American Patients with Type 2 Diabetes Mellitus and Chronic Hepatitis C Viral Infection. Endocrine Practice 17:3, 363-368.
- 81Tesfay Abreha, Yimtubezinash Woldeamanuel, Corinna Pietsch, Melanie Maier, Daniel Asrat, Almaz Abebe, Bereket Hailegiorgis, Abraham Aseffa, Uwe Gerd Liebert. (2011) Genotypes and viral load of hepatitis C virus among persons attending a voluntary counseling and testing center in Ethiopia. Journal of Medical Virology 83:5, 776-782.
- 82Erik J. Groessl, Kimberly R. Weingart, Allen L. Gifford, Steven M. Asch, Samuel B. Ho. (2011) Development of the Hepatitis C Self-Management Program. Patient Education and Counseling 83:2, 252-255.
- 83Mary Jane Burton, Imran Sunesara, Alan Penman, Huan Pham, Nora Oliver, Casey A. Young, Novell McGloster, Brendan M. McGuire. (2011) Comparing the Aspartate Aminotransferase (AST) to Platelet Ratio Index (APRI) Between African American and White Veterans with Chronic Hepatitis C. Southern Medical Journal 104:5, 309-314.
- 84Bret E. Fuller, Veronica L. Rodriguez, Alex Linke, Mirko Sikirica, Riad Dirani, Peter Hauser. (2011) Prevalence of liver disease in veterans with bipolar disorder or schizophrenia. General Hospital Psychiatry 33:3, 232-237.
- 85Thomas Astell-Burt, Robin Flowerdew, Paul J. Boyle, John F. Dillon. (2011) Does geographic access to primary healthcare influence the detection of hepatitis C?. Social Science & Medicine 72:9, 1472-1481.
- 86Choongho Lee, Han Ma, Julie Qi Hang, Vincent Leveque, Ella H. Sklan, Menashe Elazar, Klaus Klumpp, Jeffrey S. Glenn. (2011) The hepatitis C virus NS5A inhibitor (BMS-790052) alters the subcellular localization of the NS5A non-structural viral protein. Virology 414:1, 10-18.
- 87Maria Guido, Flavia Bortolotti. (2011) Viral hepatitis: Treating hepatitis C in children: an open horizon. Nature Reviews Gastroenterology & Hepatology.
- 88B. Boodram, R. C. Hershow, D. Klinzman, J. T. Stapleton. (2011) GB virus C infection among young, HIV-negative injection drug users with and without hepatitis C virus infection. Journal of Viral Hepatitis 18:4, e153-e159.
- 89M. Arshad, S. S. El-Kamary, R. Jhaveri. (2011) Hepatitis C virus infection during pregnancy and the newborn period - are they opportunities for treatment?. Journal of Viral Hepatitis 18:4, 229-236.
- 90Yi He, Jie Zhang, Li Zhong, Xue Chen, Hu-Min Liu, Li-Ke Wan, Huan Wang, Hong Li, Li Tian, Jin-Liang Hu, Ping Luo, Lei Wang, Yan Chen, Tao Liu, Shuang-Li Liu, Wen-Bin Lü. (2011) Prevalence of and risk factors for hepatitis C virus infection among blood donors in Chengdu, China. Journal of Medical Virology 83:4, 616-621.
- 91Seth Himelhoch, Richard Goldberg, Christine Calmes, Deborah Medoff, Eric Slade, Lisa Dixon, Gerard Gallucci, Stanley Rosenberg. (2011) Screening for and prevalence of HIV and Hepatitis C among an outpatient urban sample of people with serious mental illness and co-occurring substance abuse. Journal of Community Psychology 39:2, 231-239.
- 92S. Sockalingam, P. S. Links, S. E. Abbey. (2011) Suicide risk in hepatitis C and during interferon-alpha therapy: a review and clinical update. Journal of Viral Hepatitis 18:3, 153-160.
- 93Kimberly A. Forde, K. Rajender Reddy. (2011) Hormones: A Potential Explanation for Differences in Response Rates to Therapy for Chronic Hepatitis C Infection. Gastroenterology 140:3, 776-779.
- 94Markus Peck–Radosavljevic, John Boletis, Fatih Besisik, Maria Lúcia Ferraz, Laurent Alric, Didier Samuel, Diethelm Messinger, Andreas Tietz, Hugo Cheinquer. (2011) Low-Dose Peginterferon Alfa-2a Is Safe and Produces a Sustained Virologic Response in Patients With Chronic Hepatitis C and End-Stage Renal Disease. Clinical Gastroenterology and Hepatology 9:3, 242-248.
- 95Noha H. Farag, Hebat-Allah Rashed, Magda Hassan, Alaa Darweesh, Mohamed Shehata, Tarek Hassanein, Paul J. Mills. (2011) Hepatitis C infection, Cognition, and inflammation in an Egyptian sample. Journal of Medical Virology 83:2, 261-266.
- 96Yasuteru Kondo, Yoshiyuki Ueno, Eiji Kakazu, Koju Kobayashi, Masaaki Shiina, Keiichi Tamai, Keigo Machida, Jun Inoue, Yuta Wakui, Koji Fukushima, Noriyuki Obara, Osamu Kimura, Tooru Shimosegawa. (2011) Lymphotropic HCV strain can infect human primary naïve CD4+ cells and affect their proliferation and IFN-γ secretion activity. Journal of Gastroenterology 46:2, 232-241.
- 97E. H. Nagami, A. Y. Kim, C. E. Birch, M. J. Bowen, B. H. McGovern. (2011) A "One-Two Punch" Leading to Hepatitis C Seroconversion. Clinical Infectious Diseases 52:3, 361-363.
- 98Brian L. Pearlman. (2011) The IL-28 Genotype: How It Will Affect the Care of Patients with Hepatitis C Virus Infection. Current Gastroenterology Reports 13:1, 78-86.
- 99Fred Poordad, Dickens Theodore, Jane Sullivan, Kelly Grotzinger. (2011) Medical resource utilisation and healthcare costs in patients with chronic hepatitis C viral infection and thrombocytopenia. Journal of Medical Economics 14:2, 194-206.
- 100Tabinda Burney, Geoffrey Dusheiko. (2011) Overview of the PROVE studies evaluating the use of telaprevir in chronic hepatitis C genotype 1 patients. Expert Review of Anti-infective Therapy 9:2, 151-160.
- 101Young-Hee Yoon, Hsiao-ye Yi, Patricia C. Thomson. (2011) Alcohol-Related and Viral Hepatitis C-Related Cirrhosis Mortality among Hispanic Subgroups in the United States, 2000-2004. Alcoholism: Clinical and Experimental Research 35:2, 240-249.
- 102Kathleen B. Schwarz, Regino P. Gonzalez–Peralta, Karen F. Murray, Jean P. Molleston, Barbara A. Haber, Maureen M. Jonas, Philip Rosenthal, Parvathi Mohan, William F. Balistreri, Michael R. Narkewicz, Lesley Smith, Steven J. Lobritto, Stephen Rossi, Alexandra Valsamakis, Zachary Goodman, Patricia R. Robuck, Bruce A. Barton. (2011) The Combination of Ribavirin and Peginterferon Is Superior to Peginterferon and Placebo for Children and Adolescents With Chronic Hepatitis C. Gastroenterology 140:2, 450-458.e1.
- 103Mehwish Riaz, Muhamad Idrees, Hifza Kanwal, Firoz Kabir. (2011) An overview of Triple infection with Hepatitis B, C and D viruses. Virology Journal 8:1, 368.
- 104Chia C. Wang, Linda Cook, Kenneth A. Tapia, Sarah Holte, Meighan Krows, Arthur Bagabag, Anna Santos, Lawrence Corey, Keith R. Jerome. (2011) Cervicovaginal shedding of hepatitis C viral RNA is associated with the presence of menstrual or other blood in cervicovaginal fluids. Journal of Clinical Virology 50:1, 4-7.
- 105Pyung Gohn Goh, Min Jung Kim, Hye Jin Kim, Hyuk Soo Eun, Eui Sik Kim, Yun Jeung Kim, Soo Youn Lee, Hee Seok Moon, Eaum Seok Lee, Seok Hyun Kim, Byung Seok Lee, Heon Young Lee. (2011) Importance of Medication Adherence to Peginterferon-Ribavirin Combination Therapy in Patients with Chronic Hepatitis C. The Korean Journal of Gastroenterology 57:5, 294.
- 106Onpan Cheung, Richard K. Sterling, Jennifer Salvatori, Kim Williams, Sarah Hubbard, Velimir A. Luketic, Todd R. Stravitz, Arun J. Sanyal, Melissa J. Contos, Scott Mills, Mitchell L. Shiffman. (2011) Mild Alcohol Consumption is Not Associated With Increased Fibrosis in Patients With Chronic Hepatitis C. Journal of Clinical Gastroenterology 45:1, 76-82.
- 107Melanie C.M. Murray, Rolando Barrios, Wendy Zhang, Mark Hull, Valentina Montessori, Robert S. Hogg, Julio S.G. Montaner. (2011) Hepatitis C virus treatment rates and outcomes in HIV/hepatitis C virus co-infected individuals at an urban HIV clinic. European Journal of Gastroenterology & Hepatology 23:1, 45-50.
- 108Jae Young Jang, Raymond T. Chung. (2011) Chronic Hepatitis C. Gut and Liver 5:2, 117.
- 109Vjollca Durro, Shpetim Qyra. (2011) Trends in prevalence of hepatitis B virus infection among Albanian blood donors, 1999-2009. Virology Journal 8:1, 96.
- 110Diana Nurutdinova, Arbi B Abdallah, Susan Bradford, Catina C O'Leary, Linda B Cottler. (2011) Risk factors associated with Hepatitis C among female substance users enrolled in community-based HIV prevention studies. BMC Research Notes 4:1, 126.
- 111Yasuteru Kondo, Yoshiyuki Ueno, Tooru Shimosegawa. (2011) Dysfunction of Immune Systems and Host Genetic Factors in Hepatitis C Virus Infection with Persistent Normal ALT. Hepatitis Research and Treatment 2011, 1-7.
- 112Janet I. Andrews. 2011. Hepatitis Virus Infections. , 469-477..
- 113Robertson D. Davenport, Paul D. Mintz. 2011. Transfusion Medicine. , 731-745..
- 114Matthew R. Pincus, Philip M. Tierno, Maly Fenelus, Wilbur B. Bowne, Martin H. Bluth. 2011. Evaluation of Liver Function. , 296-311..
- 115Varun Saxena, Jennifer C. Lai, Jacqueline G. O'Leary, Elizabeth C. Verna, Robert S. Brown, R. Todd Stravitz, James F. Trotter, Kartik Krishnan, Norah A. Terrault, . (2011) Donor-recipient race mismatch in African-American liver transplant patients with chronic hepatitis C. Liver Transplantationn/a-n/a.
- 116Heidi Yeh, Elizabeth Smoot, David A. Schoenfeld, James F. Markmann. (2010) Geographic Inequity in Access to Livers for Transplantation. Transplantation1.
- 117Ju Dong Yang, Lewis R. Roberts. (2010) Epidemiology and Management of Hepatocellular Carcinoma. Infectious Disease Clinics of North America 24:4, 899-919.
- 118Stacey B. Trooskin, Maricruz Vega, Steven K. Herrine, A. Scott McNeal, Robert J. Winn, David J. Axelrod, Victor J. Navarro. (2010) Prevalence of HCV Risk Factors in Hispanic-American Sub Populations. Journal of Immigrant and Minority Health 12:6, 915-920.
- 119Diane M. Settles, Rakesh Vinayek. (2010) Hepatitis C and End-stage Liver Disease. Current Hepatitis Reports 9:4, 243-252.
- 120Naveen C. Srivastav, Neeraj Shakya, Michelle Mak, Chao Liang, D. Lorne J. Tyrrell, Babita Agrawal, Rakesh Kumar. (2010) Synthesis and in vitro antiviral activities of 3′-fluoro (or chloro) and 2′,3′-difluoro 2′,3′-dideoxynucleoside analogs against hepatitis B and C viruses. Bioorganic & Medicinal Chemistry 18:21, 7542-7547.
- 121Khoa D. Lam, Huy N. Trinh, Son T. Do, Thuan T. Nguyen, Ruel T. Garcia, Tuan Nguyen, Quang Q. Phan, Huy A. Nguyen, Khanh K. Nguyen, Long H. Nguyen, Mindie H. Nguyen. (2010) Randomized controlled trial of pegylated interferon-alfa 2a and ribavirin in treatment-naive chronic hepatitis C genotype 6. Hepatology 52:5, 1573-1580.
- 122Siavash Jafari, Ray Copes, Souzan Baharlou, Mahyar Etminan, Jane Buxton. (2010) Tattooing and the risk of transmission of hepatitis C: a systematic review and meta-analysis. International Journal of Infectious Diseases 14:11, e928-e940.
- 123Suganya Selvarajah, Leslie H Tobler, Graham Simmons, Michael P Busch. (2010) Host genetic basis for hepatitis C virus clearance: a role for blood collection centers. Current Opinion in Hematology 17:6, 550-557.
- 124D. M. Evon, K. M. Simpson, D. Esserman, A. Verma, S. Smith, M. W. Fried. (2010) Barriers to accessing care in patients with chronic hepatitis C: the impact of depression. Alimentary Pharmacology & Therapeutics 32:9, 1163-1173.
- 125Shailaja Jamma, Ghazi Hussain, Daryl T.-Y. Lau. (2010) Current Concepts of HBV/HCV Coinfection: Coexistence, but Not Necessarily in Harmony. Current Hepatitis Reports 9:4, 260-269.
- 126Luis A Balart, Mauricio Lisker-Melman, Fayez M Hamzeh, Ambrose Kwok, Ellen Lentz, Maribel Rodriguez-Torres. (2010) Peginterferon α-2a Plus Ribavirin in Latino and Non-Latino Whites With HCV Genotype 1: Histologic Outcomes and Tolerability From the LATINO Study. The American Journal of Gastroenterology 105:10, 2177-2185.
- 127Herbert A. Perkins, Michael P. Busch. (2010) Transfusion-associated infections: 50 years of relentless challenges and remarkable progress. Transfusion 50:10, 2080-2099.
- 128Robert J. Basseri, Michael T. Schmidt, Benjamin Basseri. (2010) Autoimmune hemolytic anemia in treatment-naive chronic hepatitis C infection: a case report and review of literature. Clinical Journal of Gastroenterology 3:5, 237-242.
- 129Harel Dahari, Stephen M. Feinstone, Marian E. Major. (2010) Meta-Analysis of Hepatitis C Virus Vaccine Efficacy in Chimpanzees Indicates an Importance for Structural Proteins. Gastroenterology 139:3, 965-974.
- 130Jonathan Krakoff, Jeanne M. Clark, Jill P. Crandall, Charlton Wilson, Mark E. Molitch, Frederick L. Brancati, Sharon L. Edelstein, William C. Knowler. (2010) Effects of Metformin and Weight Loss on Serum Alanine Aminotransferase Activity in the Diabetes Prevention Program. Obesity 18:9, 1762-1767.
- 131Zohreh Sharifi, Mahmood Mahmoodian Shooshtari, Fahimeh Rangbar Kermani. (2010) Identification of HCV genotypes in HCV infected blood donors. Indian Journal of Microbiology 50:3, 275-279.
- 132Grazia Sellitto, Aurora Faruolo, Paolo de Caprariis, Sergio Altamura, Giacomo Paonessa, Gennaro Ciliberto. (2010) Synthesis and anti-hepatitis C virus activity of novel ethyl 1H-indole-3-carboxylates in vitro. Bioorganic & Medicinal Chemistry 18:16, 6143-6148.
- 133Ju Dong Yang, Lewis R. Roberts. (2010) Hepatocellular carcinoma: a global view. Nature Reviews Gastroenterology & Hepatology 7:8, 448-458.
- 134Michael R Narkewicz, Philip Rosenthal, Kathleen B Schwarz, Arlene Drack, Todd Margolis, Michael X Repka. (2010) Ophthalmologic Complications in Children With Chronic Hepatitis C Treated With Pegylated Interferon. Journal of Pediatric Gastroenterology and Nutrition 51:2, 183-186.
- 135Xiaoan Zhang, Xiaofeng Fan, Yanjuan Xu, Adrian M. Di Bisceglie. (2010) Enhanced protocol for determining the 3′ terminus of hepatitis C virus. Journal of Virological Methods 167:2, 158-164.
- 136Eric Chak, Sammy Saab. (2010) Pegylated Interferon and Ribavirin Dosing Strategies to Enhance Sustained Virologic Response. Current Hepatitis Reports 9:3, 147-154.
- 137Benjamin Basseri, David Yamini, Grace Chee, Pharm D. Pedram Enayati, Tram Tran, Fred Poordad. (2010) Comorbidities associated with the increasing burden of hepatitis C infection. Liver International 30:7, 1012-1018.
- 138Aymin Delgado-Borrego, David Healey, Betania Negre, Marielle Christofi, Sabina Sabharwal, David A Ludwig, Raymond T Chung, Maureen M Jonas. (2010) Influence of Body Mass Index on Outcome of Pediatric Chronic Hepatitis C Virus Infection. Journal of Pediatric Gastroenterology and Nutrition 51:2, 191-197.
- 139Carolina Posada, David J. Moore, Steven Paul Woods, Ofilio Vigil, Chris Ake, William Perry, Tarek I. Hassanein, Scott L. Letendre, Igor Grant, the HIV Neurobehavioral Research Ce. (2010) Implications of hepatitis C virus infection for behavioral symptoms and activities of daily living. Journal of Clinical and Experimental Neuropsychology 32:6, 637-644.
- 140Licui Wang, Qiuxia Fu, Yafeng Dong, Yong Zhou, Shuaizheng Jia, Juan Du, Fang Zhao, Yingli Wang, Xiaohui Wang, Jianchun Peng, Shuhua Yang, Linsheng Zhan. (2010) Bioluminescence imaging of Hepatitis C virus NS3/4A serine protease activity in cells and living animals. Antiviral Research 87:1, 50-56.
- 141Hanneke van Soest, Peter J. van der Schaar, Ger H. Koek, Richard A. de Vries, Nancy A. van Ooteghem, Bart van Hoek, Joost P.H. Drenth, Jan M. Vrolijk, Rob J. Lieverse, Peter Houben, Annet van der Sluys Veer, Peter D. Siersema, Marguerite E.I. Schipper, Karel J. van Erpecum, Greet J. Boland. (2010) No beneficial effects of amantadine in treatment of chronic hepatitis C patients. Digestive and Liver Disease 42:7, 496-502.
- 142Benjamin J. Morasco, Marilyn Huckans, Jennifer M. Loftis, Jonathan Woodhouse, Adriana Seelye, Dennis C. Turk, Peter Hauser. (2010) Predictors of pain intensity and pain functioning in patients with the hepatitis C virus. General Hospital Psychiatry 32:4, 413-418.
- 143Kelly P. Burke, Andrea L. Cox. (2010) Hepatitis C virus evasion of adaptive immune responses: a model for viral persistence. Immunologic Research 47:1-3, 216-227.
- 144Latha G. Nair, Stephane Bogen, Frank Bennett, Kevin Chen, Bancha Vibulbhan, Yuhua Huang, Weing Yang, Ronald J. Doll, N.-Y. Shih, F. George Njoroge. (2010) Design and synthesis of novel fluoro amino acids: synthons for potent macrocyclic HCV NS3 protease inhibitors. Tetrahedron Letters 51:23, 3057-3061.
- 145Akira Matsumori, Miho Shimada, Tsutomu Obata. (2010) Leukocytes are the major target of hepatitis C virus infection: Possible mechanism of multiorgan involvement including the heart. CVD Prevention and Control 5:2, 51-58.
- 146A.E. Shafii, J.W. Su, N.G. Smedira, J.L. Navia, D.O. Taylor, R.C. Starling, G. Gonzalez-Stawinski. (2010) The Effect of Recipient Hepatitis C Virus Infection on Outcomes Following Heart Transplantation. Transplantation Proceedings 42:5, 1784-1787.
- 147Jeanette J. McCarthy, Josephine H. Li, Alexander Thompson, Sunil Suchindran, Xiang Qian Lao, Keyur Patel, Hans L. Tillmann, Andrew J. Muir, John G. McHutchison. (2010) Replicated Association Between an IL28B Gene Variant and a Sustained Response to Pegylated Interferon and Ribavirin. Gastroenterology 138:7, 2307-2314.
- 148R. F. Gillum, Cheryl L. Holt. (2010) Religious Involvement and Seroprevalence of Six Infectious Diseases in US Adults. Southern Medical Journal 103:5, 403-408.
- 149Matthew G. LaPorte, Tandy L. Draper, Lori E. Miller, Charles W. Blackledge, Lara K. Leister, Eugene Amparo, Alison R. Hussey, Dorothy C. Young, Srinivas K. Chunduru, Christopher A. Benetatos, Gerry Rhodes, Ariamala Gopalsamy, Torsten Herbertz, Christopher J. Burns, Stephen M. Condon. (2010) The discovery and structure–activity relationships of pyrano[3,4-b]indole based inhibitors of hepatitis C virus NS5B polymerase. Bioorganic & Medicinal Chemistry Letters 20:9, 2968-2973.
- 150Nazish Bostan, Tariq Mahmood. (2010) An overview about hepatitis C: A devastating virus. Critical Reviews in Microbiology 36:2, 91-133.
- 151K. Yusim, W. Fischer, H. Yoon, J. Thurmond, P. W. Fenimore, G. Lauer, B. Korber, C. Kuiken. (2010) Genotype 1 and global hepatitis C T-cell vaccines designed to optimize coverage of genetic diversity. Journal of General Virology 91:5, 1194-1206.
- 152L. RAGAB, S. HELAL, N. ZAGHLOUL, M. EL-RAZIKY, R. AFIFI, K. M. MUSALLAM, A. T. TAHER. (2010) Clinicovirologic analysis of hepatitis C infection in transfusion-dependent β-thalassemia major children. International Journal of Laboratory Hematology 32:2, 184-190.
- 153Christine Meffre, Yann Le Strat, Elisabeth Delarocque-Astagneau, Fréderic Dubois, Denise Antona, Jean-Marie Lemasson, Josiane Warszawski, Josiane Steinmetz, Dominique Coste, Jean-François Meyer, Sandrine Leiser, Jean-Pierre Giordanella, René Gueguen, Jean-Claude Desenclos. (2010) Prevalence of hepatitis B and hepatitis C virus infections in France in 2004: Social factors are important predictors after adjusting for known risk factors. Journal of Medical Virology 82:4, 546-555.
- 154Omar Mohamed E. Abdel Salam, Amany A. Sleem, Nermeen Shafee. (2010) Hepatoprotective effects of the nitric oxide donor isosorbide-5-mononitrate alone and in combination with the natural hepatoprotectant, silymarin, on carbon tetrachloride-induced hepatic injury in rats. Inflammopharmacology 18:2, 87-94.
- 155Frank Bennett, Yuhua Huang, Siska Hendrata, Raymond Lovey, Stephane L. Bogen, Weidong Pan, Zhuyan Guo, Andrew Prongay, Kevin X. Chen, Ashok Arasappan, Srikanth Venkatraman, Francisco Velazquez, Latha Nair, Mousumi Sannigrahi, Xiao Tong, John Pichardo, Kuo-Chi Cheng, Viyyoor M. Girijavallabhan, Anil K. Saksena, F. George Njoroge. (2010) The introduction of P4 substituted 1-methylcyclohexyl groups into Boceprevir®: A change in direction in the search for a second generation HCV NS3 protease inhibitor. Bioorganic & Medicinal Chemistry Letters 20:8, 2617-2621.
- 156Katherine E McGoogan, P Brian Smith, Steve S Choi, Wallace Berman, Ravi Jhaveri. (2010) Performance of the AST-to-Platelet Ratio Index as a Noninvasive Marker of Fibrosis in Pediatric Patients With Chronic Viral Hepatitis. Journal of Pediatric Gastroenterology and Nutrition 50:3, 344-346.
- 157Charalabos-Markos Dintsios, Alexander Haverkamp, Johannes Wiegand, Tilman Gerlach, Heiner Wedemeyer, Gerd Pape, Michael Peter Manns, Christian Krauth. (2010) Economic evaluation of early monotherapy versus delayed monotherapy or combination therapy in patients with acute hepatitis C in Germany. European Journal of Gastroenterology & Hepatology 22:3, 278-288.
- 158I. M. V. G. de Carvalho-Mello, J. E. M. Filho, M. S. Gomes-Gouvea, F. de Mello Malta, A. T. L. de Queiroz, J. R. R. Pinho, F. J. Carrilho. (2010) Molecular evidence of horizontal transmission of hepatitis C virus within couples. Journal of General Virology 91:3, 691-696.
- 159K. E. Corey, J. Mendez-Navarro, E. C. Gorospe, H. Zheng, R. T. Chung. (2010) Early treatment improves outcomes in acute hepatitis C virus infection: a meta-analysis. Journal of Viral Hepatitis 17:3, 201-207.
- 160Stéphane L. Bogen, Ashok Arasappan, Francisco Velazquez, Melissa Blackman, Regina Huelgas, Weidong Pan, Elise Siegel, Latha G. Nair, Srikanth Venkatraman, Zhuyan Guo, Ronald Doll, Neng-Yang Shih, F. George Njoroge. (2010) Discovery of potent sulfonamide P4-capped ketoamide second generation inhibitors of hepatitis C virus NS3 serine protease with favorable pharmacokinetic profiles in preclinical species. Bioorganic & Medicinal Chemistry 18:5, 1854-1865.
- 161Brian J. McMahon, Dana Bruden, Michael G. Bruce, Stephen Livingston, Carol Christensen, Chriss Homan, Thomas W. Hennessy, James Williams, Daniel Sullivan, Hugo R. Rosen, David Gretch. (2010) Adverse Outcomes in Alaska Natives Who Recovered From or Have Chronic Hepatitis C Infection. Gastroenterology 138:3, 922-931.e1.
- 162Latha G. Nair, Stephane Bogen, Sumei Ruan, Weidong Pan, Russel Pike, Xiao Tong, Kuo-Chi Cheng, Zhuyan Guo, Ronald J. Doll, F. George Njoroge. (2010) Towards the second generation of Boceprevir: Dithianes as an alternative P2 substituent for 2,2-dimethyl cycloproyl proline in HCV NS3 protease inhibitors. Bioorganic & Medicinal Chemistry Letters 20:5, 1689-1692.
- 163Ajit Sood, Vandana Midha, Neena Sood, Amarjit Kaur, Sandeep Puri. (2010) Response to antiviral treatment in patients with chronic hepatitis C with persistently normal liver enzymes. Indian Journal of Gastroenterology 29:2, 90-91.
- 164Hitoshi Ohto, Tsutomu Ishii, Junichi Kitazawa, Seiji Sugiyama, Niro Ujiie, Keiya Fujimori, Hiromichi Ariga, Tomoko Satoh, Kenneth E. Nollet, Hiroaki Okamoto, Tanji Hoshi. (2010) TRANSFUSION COMPLICATIONS: Declining hepatitis C virus (HCV) prevalence in pregnant women: impact of anti-HCV screening of donated blood. Transfusion 50:3, 693-700.
- 165Philip R Spradling, James T Richardson, Kate Buchacz, Anne C Moorman, Lyn Finelli, Beth P Bell, John T Brooks. (2010) Trends in Hepatitis C Virus Infection Among Patients in the HIV Outpatient Study, 1996-2007. JAIDS Journal of Acquired Immune Deficiency Syndromes 53:3, 388-396.
- 166Jeffery M. Klco, Bob Geng, Elizabeth M. Brunt, Anjum Hassan, Tu-Dung Nguyen, Friederike H. Kreisel, Mauricio Lisker-Melman, John L. Frater. (2010) Bone marrow biopsy in patients with hepatitis C virus infection: Spectrum of findings and diagnostic utility. American Journal of Hematology 85:2, 106-110.
- 167Gary L. Davis, Miriam J. Alter, Hashem El–Serag, Thierry Poynard, Linda W. Jennings. (2010) Aging of Hepatitis C Virus (HCV)-Infected Persons in the United States: A Multiple Cohort Model of HCV Prevalence and Disease Progression. Gastroenterology 138:2, 513-521.e6.
- 168Jennifer G. Plebani, Carlos F. Tirado, Helen M. Pettinati, Kyle M. Kampman, Joseph R. Volpicelli, David W. Oslin. (2010) Combined effects of alcohol and hepatitis C: A secondary analysis of alcohol use biomarkers and high-risk behaviors from two medication trials for alcohol dependence. Addictive Behaviors 35:2, 123-128.
- 169D. R. SILVA, J. STIFFT, H. CHEINQUER, M. M. KNORST. (2010) Prevalence of hepatitis C virus infection in patients with COPD. Epidemiology and Infection 138:02, 167.
- 170Naoyuki Nishimura, Norio Isoda, Toshihiko Higashizawa, Toshiya Otake, Mamiko Tsukui, Shigeo Nagashima, Masaharu Takahashi, Hiroaki Okamoto, Kentaro Sugano. (2010) A case of acute hepatitis C caused by interspousal transmission after 30 years of marriage. Clinical Journal of Gastroenterology 3:1, 50-56.
- 171Andrea A Howard, Donald R Hoover, Kathryn Anastos, Xi Wu, Qiuhu Shi, Howard D Strickler, Stephen R Cole, Mardge H Cohen, Andrea Kovacs, Michael Augenbraun, Patricia S Latham, Phyllis C Tien. (2010) The Effects of Opiate Use and Hepatitis C Virus Infection on Risk of Diabetes Mellitus in the Women's Interagency HIV Study. JAIDS Journal of Acquired Immune Deficiency Syndromes1.
- 172Sanjaya K. Satapathy, Chandra Sekhar Lingisetty, Shawnette Proper, Shobhana Chaudhari, Susan Williams. (2010) Equally Poor Outcomes to Pegylated Interferon-based Therapy in African Americans and Hispanics With Chronic Hepatitis C Infection. Journal of Clinical Gastroenterology 44:2, 140-145.
- 173Chia-Yen Dai, Chi-Kung Ho, Jee-Fu Huang, Ming-Yen Hsieh, Nai-Jen Hou, Zu-Yau Lin, Shinn-Cherng Chen, Ming-Yuh Hsieh, Liang-Yen Wang, Wen-Yu Chang, Ming-Lung Yu, Wan-Long Chuang. (2010) Hepatitis C virus viremia and low platelet count: A study in a hepatitis B & C endemic area in Taiwan. Journal of Hepatology 52:2, 160-166.
- 174Su-Hyung Park, Mi-Young Song, Hyo Jung Nam, Se Jin Im, Young-Chul Sung. (2010) Codelivery of IL-7 Augments Multigenic HCV DNA Vaccine-induced Antibody as well as Broad T Cell Responses in Cynomolgus Monkeys. Immune Network 10:6, 198.
- 175Michael P. Wilson, Edward M. Castillo, Andrew M. Batey, Jeffrey Sapyta, Sari Aronson. (2010) Hepatitis C and Depressive Symptoms: Psychological and Social Factors Matter More Than Liver Injury. The International Journal of Psychiatry in Medicine 40:2, 199-215.
- 176C. Kent Martin, Jeffrey E. Hostetter, John J. Hagan. (2010) New Opportunities for the Management and Therapy of Hepatitis C in Correctional Settings. American Journal of Public Health 100:1, 13-17.
- 177Latha G. Nair, Mousumi Sannigrahi, Stephane Bogen, Patrick Pinto, Kevin X. Chen, Andrew Prongay, Xiao Tong, K.-C. Cheng, Viyyoor Girijavallabhan, F. George Njoroge. (2010) P4 capped amides and lactams as HCV NS3 protease inhibitors with improved potency and DMPK profile. Bioorganic & Medicinal Chemistry Letters 20:2, 567-570.
- 178Mariana Cherner, Paola Suarez, Corinna Casey, Robert Deiss, Scott Letendre, Thomas Marcotte, Florin Vaida, J. Hampton Atkinson, Igor Grant, Robert K. Heaton. (2010) Methamphetamine use parameters do not predict neuropsychological impairment in currently abstinent dependent adults. Drug and Alcohol Dependence 106:2-3, 154-163.
- 179Mobin Khan, Md. Golam Mustafa, Nooruddin Ahmad, Md. Shahinul Alam, Rahat Hasan Baig, Ziaur Rahman Chowdhry, Mostaq Ahmed. (2010) Seroprevalence of hepatitis C virus in rural population of Bangladesh. Indian Journal of Gastroenterology 29:1, 44-45.
- 180Sumeet K. Asrani, Paula Buchanan, Brett Pinsky, Lisa Rocca Rey, Mark Schnitzler, Fasiha Kanwal. (2010) Lack of Association Between Hepatitis C Infection and Chronic Kidney Disease. Clinical Gastroenterology and Hepatology 8:1, 79-84.
- 181Gennady I. Ruban, Vladimir V. Berdnik, Dmitry V. Marinitch, Natalia V. Goncharova, Valery A. Loiko. (2010) Light scattering and morphology of the lymphocyte as applied to flow cytometry for distinguishing healthy and infected individuals. Journal of Biomedical Optics 15:5, 057008.
- 182Edmund J. Bini, Ponni V. Perumalswami. (2010) Hepatitis B virus infection among American patients with chronic hepatitis C virus infection: Prevalence, racial/ethnic differences, and viral interactions. HepatologyNA-NA.
- 183Jacqueline G. O'Leary, Gary L. Davis. 2010. Hepatitis C. , 1313-1335..
- 184David A. Guss, Leslie C. Oyama. 2010. Disorders of the Liver and Biliary Tract. , 1153-1171..
- 185Tenagne Haile-Mariam, Michael Alan Polis. 2010. Viral Illnesses. , 1700-1722..
- 186Annunziata Faustini, Paola Colais, Emanuele Fabrizi, Anna Bargagli, Marina Davoli, Domenico Di Lallo, Anteo Di Napoli, Patrizio Pezzotti, Chiara Sorge, Rita Grillo, Carla Maresca, Olga Recchia, Carlo A Perucci, . (2010) Hepatic and extra-hepatic sequelae, and prevalence of viral hepatitis C infection estimated from routine data in at-risk groups. BMC Infectious Diseases 10:1, 97.
- 187Kevin X. Chen, F. George Njoroge. 2010. The Journey to the Discovery of Boceprevir. , 1-36..
- 188Yeon-Soon Ahn. (2010) Infectious Diseases among Healthcare Workers. Journal of the Korean Medical Association 53:6, 454.
- 189JULES L. DIENSTAG. 2010. Chronic Viral Hepatitis. , 1593-1617..
- 190Rafael Guerrero-Preston, Abby Siegel, John Renz, David Vlahov, Alfred Neugut. (2009) HCV Infection and Cryptogenic Cirrhosis are Risk Factors for Hepatocellular Carcinoma Among Latinos in New York City. Journal of Community Health 34:6, 500-505.
- 191Loredana Sansonno, Felicia Anna Tucci, Silvia Sansonno, Gianfranco Lauletta, Laura Troiani, Domenico Sansonno. (2009) B cells and HCV: An infection model of autoimmunity. Autoimmunity Reviews 9:2, 93-94.
- 192M. Acalovschi, C. Buzas, C. Radu, M. Grigorescu. (2009) Hepatitis C virus infection is a risk factor for gallstone disease: a prospective hospital-based study of patients with chronic viral C hepatitis. Journal of Viral Hepatitis 16:12, 860-866.
- 193Ted Myers, Dan Allman, Kunyong Xu, Robert S. Remis, Jeffrey Aguinaldo, Ann Burchell, Liviana Calzavara, Carol Swantee. (2009) The prevalence and correlates of hepatitis C virus (HCV) infection and HCV–HIV co-infection in a community sample of gay and bisexual men. International Journal of Infectious Diseases 13:6, 730-739.
- 194W. Ray Kim, Norah A. Terrault, Rachel A. Pedersen, Terry M. Therneau, Erick Edwards, Andrew A. Hindman, Carol L. Brosgart. (2009) Trends in Waiting List Registration for Liver Transplantation for Viral Hepatitis in the United States. Gastroenterology 137:5, 1680-1686.
- 195Ma Somsouk, Hal F. Yee, Scott W. Biggins. (2009) Understanding Liver Health Using the National Center for Health Statistics. Digestive Diseases and Sciences 54:11, 2325-2329.
- 196Katherine Bornschlegel, Magdalena Berger, Renu K. Garg, Amado Punsalang, Christy M. McKinney, R. Charon Gwynn, Lorna E. Thorpe. (2009) Prevalence of Hepatitis C Infection in New York City, 2004. Journal of Urban Health 86:6, 909-917.
- 197David A. Ellis, Julie K. Blazel, Chinh V. Tran, Frank Ruebsam, Douglas E. Murphy, Lian-Sheng Li, Jingjing Zhao, Yuefen Zhou, Helen M. McGuire, Alan X. Xiang, Stephen E. Webber, Qiang Zhao, Qing Han, Charles R. Kissinger, Matthew Lardy, Alberto Gobbi, Richard E. Showalter, Amit M. Shah, Mei Tsan, Rupal A. Patel, Laurie A. LeBrun, Ruhi Kamran, Darian M. Bartkowski, Thomas G. Nolan, Daniel A. Norris, Maria V. Sergeeva, Leo Kirkovsky. (2009) 5,5′- and 6,6′-Dialkyl-5,6-dihydro-1H-pyridin-2-ones as potent inhibitors of HCV NS5B polymerase. Bioorganic & Medicinal Chemistry Letters 19:21, 6047-6052.
- 198Andre Boonstra, Luc J. W. van der Laan, Thomas Vanwolleghem, Harry L. A. Janssen. (2009) Experimental models for hepatitis C viral infection. Hepatology 50:5, 1646-1655.
- 199Michael D. Stein, Debra S. Herman, Bradley J. Anderson. (2009) A Trial to Reduce Hepatitis C Seroincidence in Drug Users. Journal of Addictive Diseases 28:4, 389-398.
- 200L. A. King, Y. Le Strat, C. Meffre, E. Delarocque-Astagneau, J.-C. Desenclos. (2009) Assessment and proposal of a new combination of screening criteria for hepatitis C in France. The European Journal of Public Health 19:5, 527-533.
- 201Javier de Vicente, Robert T. Hendricks, David B. Smith, Jay B. Fell, John Fischer, Stacey R. Spencer, Peter J. Stengel, Peter Mohr, John E. Robinson, James F. Blake, Ramona K. Hilgenkamp, Calvin Yee, Junping Zhao, Todd R. Elworthy, Jahari Tracy, Elbert Chin, Jim Li, Al Lui, Beihan Wang, Connie Oshiro, Seth F. Harris, Manjiri Ghate, Vincent J.P. Leveque, Isabel Najera, Sophie Le Pogam, Sonal Rajyaguru, Gloria Ao-Ieong, Ludmila Alexandrova, Bill Fitch, Michael Brandl, Mohammad Masjedizadeh, Shao-yong Wu, Steve de Keczer, Tatyana Voronin. (2009) Non-nucleoside inhibitors of HCV polymerase NS5B. Part 3: Synthesis and optimization studies of benzothiazine-substituted tetramic acids. Bioorganic & Medicinal Chemistry Letters 19:19, 5648-5651.
- 202Javier de Vicente, Robert T. Hendricks, David B. Smith, Jay B. Fell, John Fischer, Stacey R. Spencer, Peter J. Stengel, Peter Mohr, John E. Robinson, James F. Blake, Ramona K. Hilgenkamp, Calvin Yee, George Adjabeng, Todd R. Elworthy, Jim Li, Beihan Wang, Joe T. Bamberg, Seth F. Harris, April Wong, Vincent J.P. Leveque, Isabel Najera, Sophie Le Pogam, Sonal Rajyaguru, Gloria Ao-Ieong, Ludmila Alexandrova, Susan Larrabee, Michael Brandl, Andrew Briggs, Sunil Sukhtankar, Robert Farrell. (2009) Non-nucleoside inhibitors of HCV polymerase NS5B. Part 4: Structure-based design, synthesis, and biological evaluation of benzo[d]isothiazole-1,1-dioxides. Bioorganic & Medicinal Chemistry Letters 19:19, 5652-5656.
- 203(2009) Selective Synthesis of 1'(α),2'(β)-C-Dimethyl Carbocyclic Adenosine Analogue as Potential anti-HCV Agent. Bulletin of the Korean Chemical Society 30:9, 2039-2042.
- 204Shirley X. Hu, Namgyal L. Kyulo, Victor W. Xia, Donald J. Hillebrand, Ke-Qin Hu. (2009) Factors Associated With Hepatic Fibrosis In Patients With Chronic Hepatitis C. Journal of Clinical Gastroenterology 43:8, 758-764.
- 205Amani M. Ismail, Hala N. Ziada, Hussein A. Sheashaa, Ahmed B. Shehab El-Din. (2009) Decline of viral hepatitis prevalence among asymptomatic Egyptian blood donors: A glimmer of hope. European Journal of Internal Medicine 20:5, 490-493.
- 206Vincent Lo Re, Kevin Haynes, Kimberly A. Forde, A. Russell Localio, Rita Schinnar, James D. Lewis. (2009) Validity of The Health Improvement Network (THIN) for epidemiologic studies of hepatitis C virus infection. Pharmacoepidemiology and Drug Safety 18:9, 807-814.
- 207Malte Meppen, Barbara Pacini, Renzo Bazzo, Uwe Koch, Joseph F. Leone, Kenneth A. Koeplinger, Michael Rowley, Sergio Altamura, Annalise Di Marco, Fabrizio Fiore, Claudio Giuliano, Odalys Gonzalez-Paz, Ralph Laufer, Vincenzo Pucci, Frank Narjes, Cristina Gardelli. (2009) Cyclic phosphoramidates as prodrugs of 2′-C-methylcytidine. European Journal of Medicinal Chemistry 44:9, 3765-3770.
- 208Tawhida Yassin Abdel Ghaffar, Suzan Naghy, Hatem Sebaie, Magda Monaiery, Aisha Yassin Abdel Ghaffar. (2009) Pegylated α interferon 2B plus ribavirin in the treatment of HCV genotype 4 infection. The Indian Journal of Pediatrics 76:9, 895-898.
- 209Robert J. Wong, Douglas A. Corley. (2009) Survival Differences by Race/Ethnicity and Treatment for Localized Hepatocellular Carcinoma Within the United States. Digestive Diseases and Sciences 54:9, 2031-2039.
- 210R. Lee. (2009) Occupational transmission of bloodborne diseases to healthcare workers in developing countries: meeting the challenges. Journal of Hospital Infection 72:4, 285-291.
- 211S. Amini Kafi-Abad, H. Rezvan, H. Abolghasemi. (2009) Trends in prevalence of hepatitis B virus infection among Iranian blood donors, 1998-2007. Transfusion Medicine 19:4, 189-194.
- 212Kara W. Chew, Scott A. Allen, Lynn E. Taylor, Josiah D. Rich, Edward Feller. (2009) Treatment Outcomes With Pegylated Interferon and Ribavirin for Male Prisoners With Chronic Hepatitis C. Journal of Clinical Gastroenterology 43:7, 686-691.
- 213Tatjana Vilibic Cavlek, Ira Gjenero Margan, Snjezana Zidovec Lepej, Branko Kolaric, Adriana Vince. (2009) Seroprevalence, risk factors, and hepatitis C virus genotypes in groups with high-risk sexual behavior in Croatia. Journal of Medical Virology 81:8, 1348-1353.
- 214Kimberly A. Forde, K. Rajender Reddy. (2009) Hepatitis C Virus Infection and Immunomodulatory Therapies. Clinics in Liver Disease 13:3, 391-401.
- 215Joaquín Zúñiga, Viviana Romero, José Azocar, Daniel Terreros, María Inés Vargas-Rojas, Diana Torres-García, Luis Jiménez-Alvarez, Gilberto Vargas-Alarcón, Julio Granados-Montiel, Zaheed Husain, Raymond T. Chung, Chester A. Alper, Edmond J. Yunis. (2009) Protective KIR–HLA interactions for HCV infection in intravenous drug users. Molecular Immunology 46:13, 2723-2727.
- 216Gowdara Divakara Murthy, Khoa Vu, Sushma Venugopal. (2009) Prevalence and treatment of hyperlipidemia in patients with chronic hepatitis C infection. European Journal of Gastroenterology & Hepatology 21:8, 902-907.
- 217Elizabeth Kenny-Walsh. (2009) Increased liver-related mortality to hepatitis C viremia defined on the 20th anniversary of its identification. Hepatology 50:2, 349-351.
- 218Mark E. Mailliard, Mary E. Capadano, Matthew J. Hrnicek, Richard K. Gilroy, James M. Gulizia. (2009) Outcomes of a patient-to-patient outbreak of genotype 3a hepatitis C. Hepatology 50:2, 361-368.
- 219Javier de Vicente, Robert T. Hendricks, David B. Smith, Jay B. Fell, John Fischer, Stacey R. Spencer, Peter J. Stengel, Peter Mohr, John E. Robinson, James F. Blake, Ramona K. Hilgenkamp, Calvin Yee, George Adjabeng, Todd R. Elworthy, Jahari Tracy, Elbert Chin, Jim Li, Beihan Wang, Joe T. Bamberg, Rebecca Stephenson, Connie Oshiro, Seth F. Harris, Manjiri Ghate, Vincent Leveque, Isabel Najera, Sophie Le Pogam, Sonal Rajyaguru, Gloria Ao-Ieong, Ludmila Alexandrova, Susan Larrabee, Michael Brandl, Andrew Briggs, Sunil Sukhtankar, Robert Farrell, Brian Xu. (2009) Non-nucleoside inhibitors of HCV polymerase NS5B. Part 2: Synthesis and structure–activity relationships of benzothiazine-substituted quinolinediones. Bioorganic & Medicinal Chemistry Letters 19:13, 3642-3646.
- 220Daniel F. Wallace, V. Nathan Subramaniam. (2009) Co-factors in liver disease: The role of HFE-related hereditary hemochromatosis and iron. Biochimica et Biophysica Acta (BBA) - General Subjects 1790:7, 663-670.
- 221Shyam Kottilil, Michael Y. Yan, Kristin N. Reitano, Xiaozhen Zhang, Richard Lempicki, Gregg Roby, Marybeth Daucher, Jun Yang, Karoll J. Cortez, Marc Ghany, Michael A. Polis, Anthony S. Fauci. (2009) Human immunodeficiency virus and hepatitis C infections induce distinct immunologic imprints in peripheral mononuclear cells. Hepatology 50:1, 34-45.
- 222Kathleen A. Brady, Mark Weiner, Barbara J. Turner. (2009) Undiagnosed hepatitis C on the general medicine and trauma services of two urban hospitals. Journal of Infection 59:1, 62-69.
- 223Stanley Yu, Jeffrey M Douglass, Clifford Qualls, Sanjeev Arora, Jeffrey C Dunkelberg. (2009) Response to Therapy With Pegylated Interferon and Ribavirin for Chronic Hepatitis C in Hispanics Compared to Non-Hispanic Whites. The American Journal of Gastroenterology 104:7, 1686-1692.
- 224Albert Lecube, Cristina Hernández, Rafael Simó. (2009) Glucose abnormalities in non-alcoholic fatty liver disease and chronic hepatitis C virus infection: the role of iron overload. Diabetes/Metabolism Research and Reviews 25:5, 403-410.
- 225Robert T. Hendricks, Jay B. Fell, James F. Blake, John P. Fischer, John E. Robinson, Stacey R. Spencer, Peter J. Stengel, April L. Bernacki, Vincent J.P. Leveque, Sophie Le Pogam, Sonal Rajyaguru, Isabel Najera, John A. Josey, Jason R. Harris, Steven Swallow. (2009) Non-nucleoside inhibitors of HCV NS5B polymerase. Part 1: Synthetic and computational exploration of the binding modes of benzothiadiazine and 1,4-benzothiazine HCV NS5b polymerase inhibitors. Bioorganic & Medicinal Chemistry Letters 19:13, 3637-3641.
- 226C. Li, L. Lu, X. Zhang, D. Murphy. (2009) Entire genome sequences of two new HCV subtypes, 6r and 6s, and characterization of unique HVR1 variation patterns within genotype 6. Journal of Viral Hepatitis 16:6, 406-417.
- 227Akira Matsumori. (2009) Global alert and response network for hepatitis C virus-derived heart diseases: A call to action. CVD Prevention and Control 4:2, 109-118.
- 228Amy J. Harzke, Jacques G. Baillargeon, Karen J. Goodman, Sandi L. Pruitt. (2009) Liver cancer mortality among male prison inmates in Texas, 1992–2003. Preventive Medicine 48:6, 588-592.
- 229Kimberly A. Dowd, Dale M. Netski, Xiao–Hong Wang, Andrea L. Cox, Stuart C. Ray. (2009) Selection Pressure From Neutralizing Antibodies Drives Sequence Evolution During Acute Infection With Hepatitis C Virus. Gastroenterology 136:7, 2377-2386.
- 230Anu Osinusi, David Kleiner, Brad Wood, Michael Polis, Henry Masur, Shyam Kottilil. (2009) Rapid Development of Advanced Liver Fibrosis after Acquisition of Hepatitis C Infection during Primary HIV Infection. AIDS Patient Care and STDs 23:6, 403-406.
- 231Eileen M. Martin-Thormeyer, Robert H. Paul. (2009) Drug Abuse and Hepatitis C Infection as Comorbid Features of HIV Associated Neurocognitive Disorder: Neurocognitive and Neuroimaging Features. Neuropsychology Review 19:2, 215-231.
- 232Paul Strock, Joël Mossong, Karine Hawotte, Vic Arendt. (2009) Access to Treatment of Hepatitis C in Prison Inmates. Digestive Diseases and Sciences 54:6, 1325-1330.
- 233Ryota Masuzaki, Ryosuke Tateishi, Haruhiko Yoshida, Eriko Goto, Takahisa Sato, Takamasa Ohki, Jun Imamura, Tadashi Goto, Fumihiko Kanai, Naoya Kato, Hitoshi Ikeda, Shuichiro Shiina, Takao Kawabe, Masao Omata. (2009) Prospective risk assessment for hepatocellular carcinoma development in patients with chronic hepatitis C by transient elastography. Hepatology 49:6, 1954-1961.
- 234W. Ray Kim. (2009) Epidemiology of hepatitis B in the United States. Hepatology 49:S5, S28-S34.
- 235I. Zubkova, Y.H. Choi, E. Chang, K. Pirollo, T. Uren, H. Watanabe, F. Wells, A. Kachko, K. Krawczynski, M.E. Major. (2009) T-cell vaccines that elicit effective immune responses against HCV in chimpanzees may create greater immune pressure for viral mutation. Vaccine 27:19, 2594-2602.
- 236A. J. V. THOMPSON, J. G. MCHUTCHISON. (2009) Review article: investigational agents for chronic hepatitis C. Alimentary Pharmacology & Therapeutics 29:7, 689-705.
- 237J. D. Rempel, K. B. Aborsangaya, M. P. Alphonse, G. Y. Minuk. (2009) The influence of North American Aboriginal ethnicity on pro-inflammatory and anti-inflammatory cytokine responses to IFN-alpha. Journal of Viral Hepatitis 16:4, 292-297.
- 238Kenneth Freedman, Jay Nathanson. (2009) Interferon-based hepatitis C treatment in patients with pre-existing severe mental illness and substance use disorders. Expert Review of Anti-infective Therapy 7:3, 363-376.
- 239G. T. EVERSON, M. L. SHIFFMAN, J. C. HOEFS, T. R. MORGAN, R. K. STERLING, D. A. WAGNER, J. L. DESANTO, T. M. CURTO, E. C. WRIGHT, . (2009) Quantitative tests of liver function measure hepatic improvement after sustained virological response: results from the HALT-C trial. Alimentary Pharmacology & Therapeutics 29:5, 589-601.
- 240Sumalee Thitinan, Jason T. McConville. (2009) Interferon alpha delivery systems for the treatment of hepatitis C. International Journal of Pharmaceutics 369:1-2, 121-135.
- 241K. Patel, Y. Benhamou, E. M. Yoshida, K. D. Kaita, S. Zeuzem, M. Torbenson, E. Pulkstenis, G. M. Subramanian, J. G. McHutchison. (2009) An independent and prospective comparison of two commercial fibrosis marker panels (HCV FibroSURE and FIBRO Spect II) during albinterferon alfa-2b combination therapy for chronic hepatitis C. Journal of Viral Hepatitis 16:3, 178-186.
- 242James R Rodrigue, William Balistreri, Barbara Haber, Maureen M Jonas, Parvathi Mohan, Jean P Molleston, Karen F Murray, Michael R Narkewicz, Philip Rosenthal, Lesley J Smith, Kathleen B Schwarz, Patricia Robuck, Bruce Barton, Regino P González-Peralta. (2009) Impact of Hepatitis C Virus Infection on Children and Their Caregivers: Quality of Life, Cognitive, and Emotional Outcomes. Journal of Pediatric Gastroenterology and Nutrition 48:3, 341-347.
- 243A. K. Silberbogen, E. W. Ulloa, E. A. Janke, D. L. Mori. (2009) Psychosocial Issues and Mental Health Treatment Recommendations for Patients With Hepatitis C. Psychosomatics 50:2, 114-122.
- 244Norman M. Kneteman, Anita Y. M. Howe, Tiejun Gao, Jamie Lewis, Dan Pevear, Gary Lund, Donna Douglas, David F. Mercer, D. Lorne J. Tyrrell, Frederick Immermann, Inder Chaudhary, John Speth, Stephen A. Villano, John O'Connell, Marc Collett. (2009) HCV796: A selective nonstructural protein 5B polymerase inhibitor with potent anti-hepatitis C virus activity In Vitro , in mice with chimeric human livers, and in humans infected with hepatitis C virus. Hepatology 49:3, 745-752.
- 245Ayse L. Mindikoglu, Ram R. Miller. (2009) Hepatitis C in the Elderly: Epidemiology, Natural History, and Treatment. Clinical Gastroenterology and Hepatology 7:2, 128-134.
- 246J. Foucher, B. Reiller, V. Jullien, F. Léal, E. S. di Cesare, W. Merrouche, J.-M. Delile, V. de Lédinghen. (2009) FibroScan used in street-based outreach for drug users is useful for hepatitis C virus screening and management: a prospective study. Journal of Viral Hepatitis 16:2, 121-131.
- 247Kevin X. Chen, Bancha Vibulbhan, Weiying Yang, Latha G. Nair, Xiao Tong, Kuo-Chi Cheng, F. George Njoroge. (2009) Novel potent inhibitors of hepatitis C virus (HCV) NS3 protease with cyclic sulfonyl P3 cappings. Bioorganic & Medicinal Chemistry Letters 19:4, 1105-1109.
- 248Gayle E Fischer, Stephanie P Bialek, Chriss E Homan, Stephen E Livingston, Brian J McMahon. (2009) Chronic Liver Disease among Alaska-Native People, 2003–2004. The American Journal of Gastroenterology 104:2, 363-370.
- 249Nam-Joon Cho, Menashe Elazar, Anming Xiong, Wonjae Lee, Eric Chiao, Julie Baker, Curtis W Frank, Jeffrey S Glenn. (2009) Viral infection of human progenitor and liver-derived cells encapsulated in three-dimensional PEG-based hydrogel. Biomedical Materials 4:1, 011001.
- 250David R. McGivern, Stanley M. Lemon. (2009) Tumor Suppressors, Chromosomal Instability, and Hepatitis C Virus–Associated Liver Cancer. Annual Review of Pathology: Mechanisms of Disease 4:1, 399-415.
- 251Rodriguez-Torres, Maribel, Jeffers, Lennox J., Sheikh, Muhammad Y., Rossaro, Lorenzo, Ankoma-Sey, Victor, Hamzeh, Fayez M., Martin, Paul, . (2009) Peginterferon Alfa-2a and Ribavirin in Latino and Non-Latino Whites with Hepatitis C. New England Journal of Medicine 360:3, 257-267.
Full Text
- 252R. Charon Gwynn, Renu K. Garg, Bonnie D. Kerker, Thomas R. Frieden, Lorna E. Thorpe. (2009) Contributions of a Local Health Examination Survey to the Surveillance of Chronic and Infectious Diseases in New York City. American Journal of Public Health 99:1, 152-159.
- 253Natasha Walzer, Steven L Flamm. (2009) Pegylated IFN-α and ribavirin: emerging data in the treatment of special populations. Expert Review of Clinical Pharmacology 2:1, 67-76.
- 254S. Gitto, L. Micco, F. Conti, P. Andreone, M. Bernardi. (2009) Alcohol and viral hepatitis: A mini-review. Digestive and Liver Disease 41:1, 67-70.
- 255Francois H. T. Duong, Verena Christen, Shanshan Lin, Markus H. Heim. (2009) Hepatitis C virusâinduced up-regulation of protein phosphatase 2A inhibits histone modification and DNA damage repair. HepatologyNA-NA.
- 256H. PATEL, E. J. HEATHCOTE. (2009) When to treat and the benefits of treating hepatitis C in patients with haemophilia. Haemophilia 15:1, 20-32.
- 257S. Himelhoch, J. F. McCarthy, D. Ganoczy, D. Medoff, A. Kilbourne, R. Goldberg, L. Dixon, F. C. Blow. (2009) Understanding Associations Between Serious Mental Illness and Hepatitis C Virus Among Veterans: A National Multivariate Analysis. Psychosomatics 50:1, 30-37.
- 258Mark H. Swartz. 2009. The Abdomen. , 477-514..
- 259Erik J. Groessl, Kimberly R. Weingart, Robert M. Kaplan, Jack A. Clark, Allen L. Gifford, Samuel B. Ho. (2008) Living with Hepatitis C: Qualitative Interviews with Hepatitis C-infected Veterans. Journal of General Internal Medicine 23:12, 1959-1965.
- 260Lorenzo Rossaro, Christopher Aoki, Jihey Yuk, Colette Prosser, Jennifer Goforth, Frank Martinez. (2008) The Evaluation of Patients with Hepatitis C Living in Rural California via Telemedicine. Telemedicine and e-Health 14:10, 1127-1129.
- 261Larisa Stojanovič, Tomaž Lunder, Mario Poljak, Tomaž Marš, Boštjan Mlakar, Mojca Matičič. (2008) Lack of evidence for hepatitis C virus infection in association with lichen planus. International Journal of Dermatology 47:12, 1250-1256.
- 262Karsten Wursthorn, Michael P. Manns, Heiner Wedemeyer. (2008) Natural history: The importance of viral load, liver damage and HCC. Best Practice & Research Clinical Gastroenterology 22:6, 1063-1079.
- 263Andre Boonstra, Andrea M. Woltman, Harry L.A. Janssen. (2008) Immunology of hepatitis B and hepatitis C virus infections. Best Practice & Research Clinical Gastroenterology 22:6, 1049-1061.
- 264Gregory A. Smallwood, Renee Devine, Carlos Fasola, Andrei C. Stieber, Thomas G. Heffron. (2008) Does Interferon Use Prior to Liver Transplant Influence Hepatitis C Outcomes Following Transplantation?. Transplantation 86:12, 1795-1798.
- 265Soley Seren, Milton Mutchnick, Daryl Hutchinson, Ozgur Harmanci, Yusuf Bayraktar, Sean Mutchnick, Kazim Sahin, Omer Kucuk. (2008) Potential Role of Lycopene in the Treatment of Hepatitis C and Prevention of Hepatocellular Carcinoma. Nutrition and Cancer 60:6, 729-735.
- 266Naim Alkhouri, Nizar N. Zein. (2008) Hepatitis C in children and adolescents: The good, the bad, and the ugly. Current Hepatitis Reports 7:4, 145-151.
- 267Kerry N. Whitt, Jaquelyn F. Fleckenstein. (2008) Hepatitis C in African Americans. Current Hepatitis Reports 7:4, 139-144.
- 268E. A. Janke, S. McGraw, G. Garcia-Tsao, L. Fraenkel. (2008) Psychosocial Issues in Hepatitis C: A Qualitative Analysis. Psychosomatics 49:6, 494-501.
- 269Paul B. Watkins, Paul J. Seligman, John S. Pears, Mark I. Avigan, John R. Senior. (2008) Using controlled clinical trials to learn more about acute drug-induced liver injury. Hepatology 48:5, 1680-1689.
- 270Matthew G. LaPorte, Randy W. Jackson, Tandy L. Draper, Janet A. Gaboury, Kristin Galie, Torsten Herbertz, Alison R. Hussey, Susan R. Rippin, Christopher A. Benetatos, Srinivas K. Chunduru, Joel S. Christensen, Glen A. Coburn, Christopher J. Rizzo, Gerry Rhodes, John O'Connell, Anita Y. M. Howe, Tarek S. Mansour, Marc S. Collett, Daniel C. Pevear, Dorothy C. Young, Tiejun Gao, D. Lorne J. Tyrrell , Norman M. Kneteman, Christopher J. Burns, Stephen M. Condon. (2008) The Discovery of Pyrano[3,4- b ]indole-Based Allosteric Inhibitors of HCV NS5B Polymerase with In Vivo Activity. ChemMedChem 3:10, 1508-1515.
- 271Beilei Lei, Juan Du, Shuyan Li, Huanxiang Liu, Yueying Ren, Xiaojun Yao. (2008) Comparative molecular field analysis (CoMFA) and comparative molecular similarity indices analysis (CoMSIA) of thiazolone derivatives as hepatitis C virus NS5B polymerase allosteric inhibitors. Journal of Computer-Aided Molecular Design 22:10, 711-725.
- 272Renee Pozza. (2008) Clinical management of HIV/hepatitis C virus coinfection. Journal of the American Academy of Nurse Practitioners 20:10, 496-505.
- 273Amir Manzur, Abdul Hameed Siddiqui. (2008) Necrolytic acral erythema: successful treatment with topical tacrolimus ointment. International Journal of Dermatology 47:10, 1073-1075.
- 274Jennifer S. Read, Michael J. Cannon, Lawrence R. Stanberry, Susan Schuval. (2008) Prevention of Mother-to-Child Transmission of Viral Infections. Current Problems in Pediatric and Adolescent Health Care 38:9, 274-297.
- 275Sabina Sabharwal, Aymin Delgado-Borrego, Raymond T. Chung. (2008) Extrahepatic hepatitis C virus after transplantation: Diabetes and renal dysfunction. Liver Transplantation 14:S2, S51-S57.
- 276Teresa Santantonio, Johannes Wiegand, J. Tilman Gerlach. (2008) Acute hepatitis C: Current status and remaining challenges. Journal of Hepatology 49:4, 625-633.
- 277Dale M Netski, Qing Mao, Stuart C Ray, Robert S Klein. (2008) Genetic Divergence of Hepatitis C Virus: The Role of HIV-Related Immunosuppression. JAIDS Journal of Acquired Immune Deficiency Syndromes 49:2, 136-141.
- 278Xueshan Xia, Wenhua Zhao, Kok Keng Tee, Yue Feng, Yutaka Takebe, Qihan Li, Oliver G. Pybus, Ling Lu. (2008) Complete genome sequencing and phylogenetic analysis of HCV isolates from China reveals a new subtype, designated 6u. Journal of Medical Virology 80:10, 1740-1746.
- 279James Fung, Ching‐Lung Lai, Ivan Hung, John Young, Charles Cheng, Danny Wong, Man‐Fung Yuen. (2008) Chronic Hepatitis C Virus Genotype 6 Infection: Response to Pegylated Interferon and Ribavirin. The Journal of Infectious Diseases 198:6, 808-812.
- 280Minhee Kang, Uwe Nicolay. (2008) Evaluation of operational chronic infection endpoints for HCV vaccine trials. Contemporary Clinical Trials 29:5, 671-678.
- 281Frank Ruebsam, Zhongxiang Sun, Benjamin K. Ayida, Stephen E. Webber, Yuefen Zhou, Qiang Zhao, Charles R. Kissinger, Richard E. Showalter, Amit M. Shah, Mei Tsan, Rupal Patel, Laurie A. LeBrun, Ruhi Kamran, Maria V. Sergeeva, Darian M. Bartkowski, Thomas G. Nolan, Daniel A. Norris, Leo Kirkovsky. (2008) Hexahydro-pyrrolo- and hexahydro-1H-pyrido[1,2-b]pyridazin-2-ones as potent inhibitors of HCV NS5B polymerase. Bioorganic & Medicinal Chemistry Letters 18:18, 5002-5005.
- 282G.R. Ndong-Atome, M. Makuwa, O. Ouwe-Missi-Oukem-Boyer, O.G. Pybus, M. Branger, S. Le Hello, S.B. Boye-Cheik, F. Brun-Vezinet, M. Kazanji, P. Roques, S. Bisser. (2008) High prevalence of hepatitis C virus infection and predominance of genotype 4 in rural gabon. Journal of Medical Virology 80:9, 1581-1587.
- 283Michiko Shindo, Kazushige Hamada, Teruhisa Morikawa, Yuichi Harano, Tomoaki Nakajima, Tadao Okuno. (2008) In vivo interferon system assessed by 2′-5′ oligoadenylate synthetase activity in chronic hepatitis C virus patients treated with pegylated interferon and ribavirin. Hepatology Research.
- 284Nathan J. Shores, Ivana Maida, Vincent Soriano, Marina Núňez. (2008) Sexual transmission is associated with spontaneous HCV clearance in HIV-infected patients. Journal of Hepatology 49:3, 323-328.
- 285Juan F. Gallegos-Orozco, Jorge Rakela, Marianne J. Rosati, Hugo E. Vargas, Vijayan Balan. (2008) Persistence of Hepatitis C Virus in Peripheral Blood Mononuclear Cells of Sustained Viral Responders to Pegylated Interferon and Ribavirin Therapy. Digestive Diseases and Sciences 53:9, 2564-2568.
- 286Firdous A. Siddiqui, Murray N. Ehrinpreis, James Janisse, Ravi Dhar, Elizabeth May, Milton G. Mutchnick. (2008) Demographics of a large cohort of urban chronic hepatitis C patients. Hepatology International 2:3, 376-381.
- 287Roberto Gedaly, Timothy M. Clifford, Patrick P. McHugh, Hoonbae Jeon, Thomas D. Johnston, Dinesh Ranjan. (2008) Prevalent immunosuppressive strategies in liver transplantation for hepatitis C: results of a multi-center international survey. Transplant International 21:9, 867-872.
- 288M. Gambarin-Gelwan, I. M. Jacobson. (2008) Optimal dose of peginterferon and ribavirin for treatment of chronic hepatitis C. Journal of Viral Hepatitis 15:9, 623-633.
- 289Emuejevoke J. Okoh, Jay R. Bucci, James F. Simon, Stephen A. Harrison. (2008) HCV in Patients With End-Stage Renal Disease. The American Journal of Gastroenterology 103:8, 2123-2134.
- 290Sumathi Ramachandran, Guo-liang Xia, Lilia M. Ganova-Raeva, Omana V. Nainan, Yury Khudyakov. (2008) End-point limiting-dilution real-time PCR assay for evaluation of hepatitis C virus quasispecies in serum: Performance under optimal and suboptimal conditions. Journal of Virological Methods 151:2, 217-224.
- 291Andrea E. Reid. (2008) Viral hepatitis in African Americans. Current Hepatitis Reports 7:3, 120-126.
- 292Eliza M. F. Berkley, Kimberly K. Leslie, Sanjeev Arora, Clifford Qualls, Jeffrey C. Dunkelberg. (2008) Chronic Hepatitis C in Pregnancy. Obstetrics & Gynecology 112:2, Part 1, 304-310.
- 293David A. Ellis, Julie K. Blazel, Stephen E. Webber, Chinh V. Tran, Peter S. Dragovich, Zhongxiang Sun, Frank Ruebsam, Helen M. McGuire, Alan X. Xiang, Jingjing Zhao, Lian-Sheng Li, Yuefen Zhou, Qing Han, Charles R. Kissinger, Richard E. Showalter, Matthew Lardy, Amit M. Shah, Mei Tsan, Rupal Patel, Laurie A. LeBrun, Ruhi Kamran, Darian M. Bartkowski, Thomas G. Nolan, Daniel A. Norris, Maria V. Sergeeva, Leo Kirkovsky. (2008) 4-(1,1-Dioxo-1,4-dihydro-1λ6-benzo[1,4]thiazin-3-yl)-5-hydroxy-2H-pyridazin-3-ones as potent inhibitors of HCV NS5B polymerase. Bioorganic & Medicinal Chemistry Letters 18:16, 4628-4632.
- 294Maribel Rodríguez-Torres. (2008) Chronic hepatitis C in the Latino population. Current Hepatitis Reports 7:3, 106-112.
- 295Onpan Cheung, Arun J. Sanyal. (2008) Hepatitis C Infection and Nonalcoholic Fatty Liver Disease. Clinics in Liver Disease 12:3, 573-585.
- 296Wojciech Blonski, K. Rajender Reddy. (2008) Hepatitis C Virus Infection and Hepatocellular Carcinoma. Clinics in Liver Disease 12:3, 661-674.
- 297Vinod K. Rustgi, Gary L. Davis, Steven K. Herrine, Arthur J. McCullough, Scott L. Friedman, Gregory J. Gores. (2008) Future trends in hepatology: Challenges and opportunities. Hepatology 48:2, 655-661.
- 298Su-Hyung Park, Sang Rae Lee, Byung Hwa Hyun, Byong-Moon Kim, Young Chul Sung. (2008) Codelivery of PEG-IFN-α inhibits HCV DNA vaccine-induced T cell responses but not humoral responses in African green monkeys. Vaccine 26:32, 3978-3983.
- 299S. Bogen, A. Arasappan, W. Pan, S. Ruan, A. Padilla, A.K. Saksena, V. Girijavallabhan, F.G. Njoroge. (2008) Hepatitis C virus NS3-4A serine protease inhibitors: SAR of new P1 derivatives of SCH 503034. Bioorganic & Medicinal Chemistry Letters 18:14, 4219-4223.
- 300Jessica Willner-Reid, Katherine A. Belendiuk, David H. Epstein, John Schmittner, Kenzie L. Preston. (2008) Hepatitis C and human immunodeficiency virus risk behaviors in polydrug users on methadone maintenance. Journal of Substance Abuse Treatment 35:1, 78-86.
- 301Sun Hee Kim, Martin T. Tran, Frank Ruebsam, Alan X. Xiang, Benjamin Ayida, Helen McGuire, David Ellis, Julie Blazel, Chinh V. Tran, Douglas E. Murphy, Stephen E. Webber, Yuefen Zhou, Amit M. Shah, Mei Tsan, Richard E. Showalter, Rupal Patel, Alberto Gobbi, Laurie A. LeBrun, Darian M. Bartkowski, Thomas G. Nolan, Daniel A. Norris, Maria V. Sergeeva, Leo Kirkovsky, Qiang Zhao, Qing Han, Charles R. Kissinger. (2008) Structure-based design, synthesis, and biological evaluation of 1,1-dioxoisothiazole and benzo[b]thiophene-1,1-dioxide derivatives as novel inhibitors of hepatitis C virus NS5B polymerase. Bioorganic & Medicinal Chemistry Letters 18:14, 4181-4185.
- 302Marie Csete. (2008) Gender Issues in Transplantation. Anesthesia & Analgesia 107:1, 232-238.
- 303Anurag Maheshwari, Stuart Ray, Paul J Thuluvath. (2008) Acute hepatitis C. The Lancet 372:9635, 321-332.
- 304Douglas K. Hutchinson, Teresa Rosenberg, Larry L. Klein, Todd D. Bosse, Daniel P. Larson, Wenping He, Wen W. Jiang, Warren M. Kati, William E. Kohlbrenner, Yaya Liu, Sherie V. Masse, Tim Middleton, Akhteruzzaman Molla, Debra A. Montgomery, David W.A. Beno, Kent D. Stewart, Vincent S. Stoll, Dale J. Kempf. (2008) Hepatitis C NS5B polymerase inhibitors: 4,4-Dialkyl-1-hydroxy-3-oxo-3,4-dihydronaphthalene-3-yl benzothiadiazine derivatives. Bioorganic & Medicinal Chemistry Letters 18:14, 3887-3890.
- 305C. BROUARD, P. PRADAT, E. DELAROCQUE-ASTAGNEAU, C. SILVAIN. (2008) Epidemiological characteristics and medical follow-up of 61 patients with acute hepatitis C identified through the hepatitis C surveillance system in France. Epidemiology and Infection 136:07,.
- 306Steven A. Pergam, Chia C. Wang, Carolyn M. Gardella, Taylor G. Sandison, Warren T. Phipps, Stephen E. Hawes. (2008) Pregnancy complications associated with hepatitis C: data from a 2003-2005 Washington state birth cohort. American Journal of Obstetrics and Gynecology 199:1, 38.e1-38.e9.
- 307Juan Macías, Rosa B. Palacios, Evangelina Claro, Julio Vargas, Salvador Vergara, José A. Mira, Nicolás Merchante, Juan E. Corzo, Juan A. Pineda. (2008) High prevalence of hepatitis C virus infection among noninjecting drug users: association with sharing the inhalation implements of crack. Liver International 28:6, 781-786.
- 308Yoichi Hiasa, Hiroyuki Kuzuhara, Yoshio Tokumoto, Ichiro Konishi, Nobuyuki Yamashita, Bunzo Matsuura, Kojiro Michitaka, Raymond T. Chung, Morikazu Onji. (2008) Hepatitis C virus replication is inhibited by 22β-methoxyolean-12-ene-3β, 24(4β)-diol (ME3738) through enhancing interferon-β. Hepatology 48:1, 59-69.
- 309Guaniri Mateu, Ruben O. Donis, Takaji Wakita, Jens Bukh, Arash Grakoui. (2008) Intragenotypic JFH1 based recombinant hepatitis C virus produces high levels of infectious particles but causes increased cell death. Virology 376:2, 397-407.
- 310Lian-Sheng Li, Yuefen Zhou, Douglas E. Murphy, Nebojsa Stankovic, Jingjing Zhao, Peter S. Dragovich, Thomas Bertolini, Zhongxiang Sun, Benjamin Ayida, Chinh V. Tran, Frank Ruebsam, Stephen E. Webber, Amit M. Shah, Mei Tsan, Richard E. Showalter, Rupal Patel, Laurie A. LeBrun, Darian M. Bartkowski, Thomas G. Nolan, Daniel A. Norris, Ruhi Kamran, Jennifer Brooks, Maria V. Sergeeva, Leo Kirkovsky, Qiang Zhao, Charles R. Kissinger. (2008) Novel HCV NS5B polymerase inhibitors derived from 4-(1′,1′-dioxo-1′,4′-dihydro-1′λ6-benzo[1′,2′,4′]thiadiazin-3′-yl)-5-hydroxy-2H-pyridazin-3-ones. Part 3: Further optimization of the 2-, 6-, and 7′-substituents and initial pharmacokinetic assessments. Bioorganic & Medicinal Chemistry Letters 18:11, 3446-3455.
- 311Jose L. Tovar, Maria Buti, Alfonso Segarra, Joaquim Majó, Rafael Esteban. (2008) De novo nephrotic syndrome following pegylated interferon alfa 2b/ribavirin therapy for chronic hepatitis C infection. International Urology and Nephrology 40:2, 539-541.
- 312Evelyn K Hsu, Karen F Murray. (2008) Hepatitis B and C in children. Nature Clinical Practice Gastroenterology & Hepatology 5:6, 311-320.
- 313James H. Tabibian, Donna A. Wirshing, Joseph M. Pierre, Lisa H. Guzik, Michael D. Kisicki, Itai Danovitch, Shirley J. Mena, William C. Wirshing. (2008) Hepatitis B and C Among Veterans on a Psychiatric Ward. Digestive Diseases and Sciences 53:6, 1693-1698.
- 314M. Mazen Jamal, Jason B. Samarasena, Mehrtash Hashemzadeh, Kenneth J. Vega. (2008) Declining Hospitalization Rate of Esophageal Variceal Bleeding in the United States. Clinical Gastroenterology and Hepatology 6:6, 689-695.
- 315Hui Li, Brian J. McMahon, Susan McArdle, Dana Bruden, Daniel G. Sullivan, Dave Shelton, Heike Deubner, David R. Gretch. (2008) Hepatitis C virus envelope glycoprotein co-evolutionary dynamics during chronic hepatitis C. Virology 375:2, 580-591.
- 316Frank Ruebsam, Stephen E. Webber, Martin T. Tran, Chinh V. Tran, Douglas E. Murphy, Jingjing Zhao, Peter S. Dragovich, Sun Hee Kim, Lian-Sheng Li, Yuefen Zhou, Qing Han, Charles R. Kissinger, Richard E. Showalter, Matthew Lardy, Amit M. Shah, Mei Tsan, Rupal Patel, Laurie A. LeBrun, Ruhi Kamran, Maria V. Sergeeva, Darian M. Bartkowski, Thomas G. Nolan, Daniel A. Norris, Leo Kirkovsky. (2008) Pyrrolo[1,2-b]pyridazin-2-ones as potent inhibitors of HCV NS5B polymerase. Bioorganic & Medicinal Chemistry Letters 18:12, 3616-3621.
- 317Xibin Liao, Gabor Butora, David B. Olsen, Steven S. Carroll, Daniel R. McMasters, Joseph F. Leone, Mark Stahlhut, George A. Doss, Lihu Yang, Malcolm MacCoss. (2008) Synthesis of 2′-β-C-methyl-neplanocin derivatives as anti-HCV agents. Tetrahedron Letters 49:26, 4149-4152.
- 318Sharon M. Moe, A.J. Pampalone, Susan Ofner, Marc Rosenman, Evgenia Teal, Siu L. Hui. (2008) Association of Hepatitis C Virus Infection With Prevalence and Development of Kidney Disease. American Journal of Kidney Diseases 51:6, 885-892.
- 319Kenrad E. Nelson, Hua Shan. (2008) Confirmatory testing of hepatitis C virus–positive enzyme immunoassay results in limited-resource countries: should it be attempted?. Transfusion 48:6, 1239-1244.
- 320Z.M. Hassan, M.A. Wahsheh, K.R. Shishani, E.R. Pryor. (2008) Hepatitis needs assessment among Jordanian healthcare workers. International Nursing Review 55:2, 142-147.
- 321Robert Wong, Douglas A. Corley. (2008) Racial and Ethnic Variations in Hepatocellular Carcinoma Incidence within the United States. The American Journal of Medicine 121:6, 525-531.
- 322Jules L. Dienstag. (2008) Hepatitis A: The Vaccine Dividend. The Journal of Infectious Diseases 197:9, 1220-1222.
- 323Maribel Rodríguez–Torres. (2008) Latinos and Chronic Hepatitis C: A Singular Population. Clinical Gastroenterology and Hepatology 6:5, 484-490.
- 324Q-S Wang, J Yuan, S-Y Zhou, J-Q Chen. (2008) Chronic hepatitis C virus infection is not associated with Mooren's ulcer. Eye 22:5, 697-700.
- 325Christine M. Rousseau, George N. Ioannou, Jeffrey A. Todd-Stenberg, Kevin L. Sloan, Meaghan F. Larson, Christopher W. Forsberg, Jason A. Dominitz. (2008) Racial Differences in the Evaluation and Treatment of Hepatitis C Among Veterans: A Retrospective Cohort Study. American Journal of Public Health 98:5, 846-852.
- 326Mindie H. Nguyen, Huy N. Trinh, Ruel Garcia, Gloria Nguyen, Khoa D. Lam, Emmet B. Keeffe. (2008) Higher Rate of Sustained Virologic Response in Chronic Hepatitis C Genotype 6 Treated With 48 Weeks Versus 24 Weeks of Peginterferon Plus Ribavirin. The American Journal of Gastroenterology 103:5, 1131-1135.
- 327Jacqueline G. O'Leary, Rita Lepe, Gary L. Davis. (2008) Indications for Liver Transplantation. Gastroenterology 134:6, 1764-1776.
- 328Jayant N. Acharya, Vitor H. Pacheco. (2008) Neurologic Complications of Hepatitis C. The Neurologist 14:3, 151-156.
- 329J. T. Blackard, K. E. Sherman. (2008) HCV/ HIV co-infection: time to re-evaluate the role of HIV in the liver?. Journal of Viral Hepatitis 15:5, 323-330.
- 330Charles D. Howell, Thomas C. Dowling, Marika Paul, Abdus S. Wahed, Norah A. Terrault, Milton Taylor, Lennox Jeffers, Jay H. Hoofnagle. (2008) Peginterferon Pharmacokinetics in African American and Caucasian American Patients With Hepatitis C Virus Genotype 1 Infection. Clinical Gastroenterology and Hepatology 6:5, 575-583.
- 331E. Dieperink, J. Leskela, M. E. Dieperink, B. Evans, P. Thuras, S. B. Ho. (2008) The Effect of Pegylated Interferon- 2b and Ribavirin on Posttraumatic Stress Disorder Symptoms. Psychosomatics 49:3, 225-229.
- 332Nader Dbouk, Miguel R. Arguedas, Aasim Sheikh. (2008) Assessment of the PHQ-9 as a Screening Tool for Depression in Patients with Chronic Hepatitis C. Digestive Diseases and Sciences 53:4, 1100-1106.
- 333Eva A. Operskalski, Wendy J. Mack, Howard D. Strickler, Audrey L. French, Michael Augenbraun, Phyllis C. Tien, Maria C. Villacres, LaShonda Y. Spencer, Marina DeGiacomo, Andrea Kovacs. (2008) Factors associated with hepatitis C viremia in a large cohort of HIV-infected and -uninfected women. Journal of Clinical Virology 41:4, 255-263.
- 334Matthew Wise, Stephanie Bialek, Lyn Finelli, Beth P. Bell, Frank Sorvillo. (2008) Changing trends in hepatitis C-related mortality in the United States, 1995-2004. Hepatology 47:4, 1128-1135.
- 335W. Ray Kim, Steven L. Flamm, Adrian M. Di Bisceglie, Henry C. Bodenheimer. (2008) Serum activity of alanine aminotransferase (ALT) as an indicator of health and disease. Hepatology 47:4, 1363-1370.
- 336P. De, É. Roy, J.-F. Boivin, J. Cox, C. Morissette. (2008) Risk of hepatitis C virus transmission through drug preparation equipment: a systematic and methodological review. Journal of Viral Hepatitis 15:4, 279-292.
- 337Ma Somsouk, Deston E. Langfield, John M. Inadomi, Hal F. Yee. (2008) A Cost-Identification Analysis of Screening and Surveillance of Hepatitis C Infection in a Prospective Cohort of Dialysis Patients. Digestive Diseases and Sciences 53:4, 1093-1099.
- 338Marcello Romano, Marco Vacante, Erika Cristaldi, Valentina Colonna, Maria Pia Gargante, Lisa Cammalleri, Mariano Malaguarnera. (2008) l-Carnitine Treatment Reduces Steatosis in Patients with Chronic Hepatitis C Treated with α-Interferon and Ribavirin. Digestive Diseases and Sciences 53:4, 1114-1121.
- 339L. Ye, J. S. Peng, X. Wang, Y. J. Wang, G. X. Luo, W. Z. Ho. (2008) Methamphetamine enhances Hepatitis C virus replication in human hepatocytes. Journal of Viral Hepatitis 15:4, 261-270.
- 340Takamasa Ohki, Ryosuke Tateishi, Takahisa Sato, Ryota Masuzaki, Jun Imamura, Tadashi Goto, Noriyo Yamashiki, Hideo Yoshida, Fumihiko Kanai, Naoya Kato, Shuichiro Shiina, Haruhiko Yoshida, Takao Kawabe, Masao Omata. (2008) Obesity Is an Independent Risk Factor for Hepatocellular Carcinoma Development in Chronic Hepatitis C Patients. Clinical Gastroenterology and Hepatology 6:4, 459-464.
- 341Annette M. Matthews, Peter Hauser. (2008) Hepatitis C Screening in Bipolar Veterans. Addictive Disorders & Their Treatment 7:1, 41-45.
- 342Elisabeth Monnet, Cécile Ramée, Anne Minello, Valérie Jooste, Didier Carel, Vincent Di Martino. (2008) Socioeconomic context, distance to primary care and detection of hepatitis C: A French population-based study. Social Science & Medicine 66:5, 1046-1056.
- 343Tatehiro Kagawa, Hirokazu Shiozawa, Sei-ichiro Kojima, Shinji Takashimizu, Naruhiko Nagata, Makoto Numata, Fumitoshi Morino, Yasuhiro Nishizaki, Kaori Mochizuki, Norihito Watanabe, Tetsu Watanabe, Shohei Matsuzaki, Tetsuya Mine. (2008) Eight-week oral administration of meloxicam, a non-steroidal anti-inflammatory drug, prevents dose reduction of pegylated interferon α-2a in the treatment of chronic hepatitis C. Hepatology Research 38:3, 259-266.
- 344Annette M Matthews, Marilyn S Huckans, Aaron D Blackwell, Peter Hauser. (2008) Hepatitis C testing and infection rates in bipolar patients with and without comorbid substance use disorders. Bipolar Disorders 10:2, 266-270.
- 345Wulf O. Böcher, Christian Wallasch, Thomas Höhler, Peter R. Galle. (2008) All-trans retinoic acid for treatment of chronic hepatitis C. Liver International 28:3, 347-354.
- 346Edmond Vartany, Cary A. Caldwell, Terence K. Trow. (2008) Adult respiratory distress syndrome after treatment with pegylated interferon α-2a and ribavirin. Heart & Lung: The Journal of Acute and Critical Care 37:2, 153-156.
- 347J. G. MCHUTCHISON, K. PATEL, E. R. SCHIFF, N. GITLIN, R. E. MUR, G. T. EVERSON, R. L. CARITHERS, G. L. DAVIS, P. MARCELLIN, M. L. SHIFFMAN, J. HARVEY, J. K. ALBRECHT, . (2008) Clinical trial: interferon alpha-2b continuous long-term therapy vs. repeated 24-week cycles for re-treating chronic hepatitis C. Alimentary Pharmacology & Therapeutics 27:5, 422-432.
- 348Geoffrey C. Nguyen, Paul J. Thuluvath. (2008) Racial disparity in liver disease: Biological, cultural, or socioeconomic factors. Hepatology 47:3, 1058-1066.
- 349Zachary D. Goodman, Hala R. Makhlouf, Lea Liu, William Balistreri, Regino P. Gonzalez-Peralta, Barbara Haber, Maureen M. Jonas, Parvathi Mohan, Jean P. Molleston, Karen F. Murray, Michael R. Narkewicz, Philip Rosenthal, Lesley J. Smith, Patricia R. Robuck, Kathleen B. Schwarz. (2008) Pathology of chronic hepatitis C in children: Liver biopsy findings in the Peds-C Trial. Hepatology 47:3, 836-843.
- 350Daryl T.-Y. Lau, Penny Mar Fish, Mala Sinha, David M. Owen, Stanley M. Lemon, Michael Gale. (2008) Interferon regulatory factor-3 activation, hepatic interferon-stimulated gene expression, and immune cell infiltration in hepatitis C virus patients. Hepatology 47:3, 799-809.
- 351Jason Grebely, Stanley Devlaming, Fiona Duncan, Mark Viljoen, Brian Conway. (2008) Current Approaches to HCV Infection in Current and Former Injection Drug Users. Journal of Addictive Diseases 27:2, 25-35.
- 352V. González, E. Martró, C. Folch, A. Esteve, L. Matas, A. Montoliu, J. R. Grífols, F. Bolao, C. Tural, R. Muga, J. V. Parry, V. Ausina, J. Casabona. (2008) Detection of hepatitis C virus antibodies in oral fluid specimens for prevalence studies. European Journal of Clinical Microbiology & Infectious Diseases 27:2, 121-126.
- 353Keyur Patel, David R. Nelson, Don C. Rockey, Nezam H. Afdhal, Katie M. Smith, Esther Oh, Keith Hettinger, Marc Vallée, Anouk Dev, Margaret Smith–Riggs, John G. McHutchison. (2008) Correlation of FIBROSpect II With Histologic and Morphometric Evaluation of Liver Fibrosis in Chronic Hepatitis C. Clinical Gastroenterology and Hepatology 6:2, 242-247.
- 354Suzanne Norris, Diarmaid Houlihan. (2008) Liver transplantation in HIV-positive patients. Expert Review of Gastroenterology & Hepatology 2:1, 39-46.
- 355R. MARTÍN-SANTOS, C. DÍEZ-QUEVEDO, P. CASTELLVÍ, R. NAVINÉS, M. MIQUEL, H. MASNOU, A. SOLER, M. ARDEVOL, F. GARCÍA, J. A. GALERAS, R. PLANAS, R. SOLÀ. (2008) De novo depression and anxiety disorders and influence on adherence during peginterferon-alpha-2a and ribavirin treatment in patients with hepatitis C. Alimentary Pharmacology & Therapeutics 27:3, 257-265.
- 356Yuefen Zhou, Stephen E. Webber, Douglas E. Murphy, Lian-Sheng Li, Peter S. Dragovich, Chinh V. Tran, Zhongxiang Sun, Frank Ruebsam, Amit M. Shah, Mei Tsan, Richard E. Showalter, Rupal Patel, Bin Li, Qiang Zhao, Qing Han, Thomas Hermann, Charles R. Kissinger, Laurie LeBrun, Maria V. Sergeeva, Leo Kirkovsky. (2008) Novel HCV NS5B polymerase inhibitors derived from 4-(1′,1′-dioxo-1′,4′-dihydro-1′λ6-benzo[1′,2′,4′]thiadiazin-3′-yl)-5-hydroxy-2H-pyridazin-3-ones. Part 1: Exploration of 7′-substitution of benzothiadiazine. Bioorganic & Medicinal Chemistry Letters 18:4, 1413-1418.
- 357William Perry, Robin C. Hilsabeck, Tarek I. Hassanein. (2008) Cognitive Dysfunction in Chronic Hepatitis C: A Review. Digestive Diseases and Sciences 53:2, 307-321.
- 358Antonio Craxì, Giacomo Laffi, Anna Linda Zignego. (2008) Hepatitis C virus (HCV) infection: A systemic disease. Molecular Aspects of Medicine 29:1-2, 85-95.
- 359Holly Groom, Eric Dieperink, David B. Nelson, Judith Garrard, James R. Johnson, Stephen L. Ewing, Herbert Stockley, Janet Durfee, Yvonne Jonk, Mark L. Willenbring, Samuel B. Ho. (2008) Outcomes of a Hepatitis C Screening Program at a Large Urban VA Medical Center. Journal of Clinical Gastroenterology 42:1, 97-106.
- 360Carol Mallette, Maura A Flynn, Kittichai Promrat. (2008) Outcome of Screening for Hepatitis C Virus Infection Based on Risk Factors. The American Journal of Gastroenterology 103:1, 131-137.
- 361Daniel R. Lefebvre, Louise F. Strande, Charles W. Hewitt. (2008) An Enzyme-Mediated Assay to Quantify Inoculation Volume Delivered by Suture Needlestick Injury: Two Gloves Are Better Than One. Journal of the American College of Surgeons 206:1, 113-122.
- 362Eva Martínez-Bauer, Xavier Forns, Mercé Armelles, Ramon Planas, Ricard Solà, Mercé Vergara, Silvia Fàbregas, Roser Vega, Javier Salmerón, Moisés Diago, Jose María Sánchez-Tapias, Miquel Bruguera. (2008) Hospital admission is a relevant source of hepatitis C virus acquisition in Spain. Journal of Hepatology 48:1, 20-27.
- 363Myoung Joo Kang, Eun Uk Jung, Sang Won Park, Paul Choi, Ji Hyun Kim, Sung Jae Park, Eun Taek Park, Youn Jae Lee, Sang Hyuk Lee, Sang Yong Seol. (2008) Effects of pegylated interferon and ribavirin in Korean patients with chronic hepatitis C virus infection. The Korean Journal of Hepatology 14:3, 318.
- 364Ke-Qin Hu, John M. Vierling, Allan G. Redeker. (2008) Viral, host and interferon-related factors modulating the effect of interferon therapy for hepatitis C virus infection. Journal of Viral Hepatitis 8:1, 1.
- 365Muhammad Naeem Khattak, Saeed Akhtar, Sadia Mahmud, Tariq Mahmood Roshan. (2008) Factors Influencing Hepatitis C Virus Sero-prevalence among Blood Donors in North West Pakistan. Journal of Public Health Policy 29:2, 207-225.
- 366AA Modi, TJ Liang. (2008) Hepatitis C: a clinical review. Oral Diseases 14:1, 10-14.
- 367Adnan Said, Nasia Safdar, Jennifer Wells, Michael R. Lucey. 2008. Liver Disease in Renal Transplant Recipients. , 508-533..
- 368He-Jun Yuan, William M Lee. (2008) Nonresponse to Treatment for Hepatitis C. Drugs 68:1, 27-42.
- 369Steven A Pergam, Stephen E Hawes, Carolyn M Gardella, Chia C Wang. (2008) HCV and pregnancy: is now the time for universal testing?. Future Virology 3:1, 1-5.
- 370Tatsuya Aikawa, Maki Kojima, Kuniko Miyamoto, Chisato Ueno, Masaharu Takahashi, Hiroaki Okamoto. (2008) A case of acute hepatitis C, most likely by interspousal sexual transmission after 40 years of marriage. Kanzo 49:8, 352-361.
- 371Prithwish De, Joseph Cox, Jean-François Boivin, Robert W. Platt, Ann M. Jolly. (2008) Social Network-Related Risk Factors for Bloodborne Virus Infections Among Injection Drug Users Receiving Syringes through Secondary Exchange. Journal of Urban Health 85:1, 77-89.
- 372Carrie Reed, Sherri O. Stuver, Sheila Tumilty, David Nunes, Jessica E. Murray, Camilla S. Graham, Margaret James Koziel, Donald E. Craven, Paul R. Skolnik, C. Robert Horsburgh. (2008) Predictors of Treatment for Hepatitis C Virus (HCV) Infection in Drug Users. Substance Abuse 29:1, 5-15.
- 373Sue L. Currie, James C. Ryan, Daniel Tracy, Teresa L. Wright, Sally George, Rosemary McQuaid, Michael Kim, Hui Shen, Alexander Monto. (2008) A prospective study to examine persistent HCV reinfection in injection drug users who have previously cleared the virus. Drug and Alcohol Dependence 93:1-2, 148-154.
- 374Fasiha Kanwal, Tuyen Hoang, Brennan M.R. Spiegel, Seth Eisen, Jason A. Dominitz, Allen Gifford, Mathew Goetz, Steven M. Asch. (2007) Predictors of treatment in patients with chronic hepatitis C infectionRole of patient versus nonpatient factors. Hepatology 46:6, 1741-1749.
- 375Weiliang Tang, Catherine A. Lázaro, Jean S. Campbell, W. Tony Parks, Michael G. Katze, Nelson Fausto. (2007) Responses of Nontransformed Human Hepatocytes to Conditional Expression of Full-Length Hepatitis C Virus Open Reading Frame. The American Journal of Pathology 171:6, 1831-1846.
- 376Katerina Lagios, Frank P. Deane. (2007) Severe mental illness is a new risk marker for blood-borne viruses and sexually transmitted infections. Australian and New Zealand Journal of Public Health 31:6, 562-566.
- 377Karina Razali, Hla Hla Thein, Jane Bell, Mark Cooper-Stanbury, Kate Dolan, Greg Dore, Jacob George, John Kaldor, Maria Karvelas, Jiong Li, Lisa Maher, Sharyn McGregor, Margaret Hellard, Fiona Poeder, Julianne Quaine, Kim Stewart, Helen Tyrrell, Martin Weltman, Owen Westcott, Alex Wodak, Matthew Law. (2007) Modelling the hepatitis C virus epidemic in Australia. Drug and Alcohol Dependence 91:2-3, 228-235.
- 378Shimian Zou, Fatemeh Musavi, Edward P. Notari, Chyang T. Fang, . (2007) Changing age distribution of the blood donor population in the United States. Transfusion 0:0, 071117010348009-???.
- 379L. T. F. Yeung, T. To, S. M. King, E. A. Roberts. (2007) Spontaneous clearance of childhood hepatitis C virus infection. Journal of Viral Hepatitis 14:11, 797-805.
- 380Frank Yeh, Fredric D Gordon. (2007) Peginterferon alfa-2b and ribavirin combination therapy for chronic hepatitis C. Future Virology 2:6, 553-563.
- 381Omer Junaidi, Adrian M. Di Bisceglie. (2007) Aging Liver and Hepatitis. Clinics in Geriatric Medicine 23:4, 889-903.
- 382Jawad Ahmad, Kathy K. Downey, Mohamed Akoad, Thomas V. Cacciarelli. (2007) Impact of the MELD score on waiting time and disease severity in liver transplantation in United States veterans. Liver Transplantation 13:11, 1564-1569.
- 383Siobhan Sutcliffe, Sabine Rohrmann, Edward Giovannucci, Kenrad E. Nelson, Angelo M. De Marzo, William B. Isaacs, William G. Nelson, Elizabeth A. Platz. (2007) Viral Infections and Lower Urinary Tract Symptoms in the Third National Health and Nutrition Examination Survey. The Journal of Urology 178:5, 2181-2185.
- 384Marc S. Itskowitz. (2007) Hepatitis C: Epidemiology, Diagnosis, and Management. Comprehensive Therapy 33:2, 87-93.
- 385Subhas Banerjee, Douglas B. Nelson, Jason A. Dominitz, Steven O. Ikenberry, Michelle A. Anderson, Brooks D. Cash, Seng-Ian Gan, M. Edwyn Harrison, Bo Shen, Todd H. Baron, Trina Van Guilder, Kenneth K. Lee. (2007) Reprocessing failure. Gastrointestinal Endoscopy 66:5, 869-871.
- 386John G. McHutchison, Bruce R. Bacon, Stuart C. Gordon, Eric Lawitz, Mitchell Shiffman, Nezam H. Afdhal, Ira M. Jacobson, Andrew Muir, Mohammed Al-Adhami, Mary L. Morris, Julie A. Lekstrom-Himes, Susan M. Efler, Heather L. Davis. (2007) Phase 1B, randomized, double-blind, dose-escalation trial of CPG 10101 in patients with chronic hepatitis C virus. Hepatology 46:5, 1341-1349.
- 387Zania Stamataki, Stephen Coates, Matthew J. Evans, Mark Wininger, Kevin Crawford, Christine Dong, Yiu-lian Fong, David Chien, Sergio Abrignani, Peter Balfe, Charles M. Rice, Jane A. McKeating, Michael Houghton. (2007) Hepatitis C virus envelope glycoprotein immunization of rodents elicits cross-reactive neutralizing antibodies. Vaccine 25:45, 7773-7784.
- 388Carla W. Brady, Cynthia J. Coffman, Dawn Provenzale. (2007) Compliance With Referral for Hepatitis C Evaluation Among Veterans. Journal of Clinical Gastroenterology 41:10, 927-931.
- 389Th. Witthöft, B. Möller, K. H. Wiedmann, St. Mauss, R. Link, J. Lohmeyer, M. Lafrenz, C. M. Gelbmann, D. Hüppe, C. Niederau, U. Alshuth. (2007) Safety, tolerability and efficacy of peginterferon alpha-2a and ribavirin in chronic hepatitis C in clinical practice: The German Open Safety Trial. Journal of Viral Hepatitis 14:11, 788-796.
- 390Prithwish De, Joseph Cox, Jean-François Boivin, Robert W. Platt, Ann M. Jolly. (2007) The importance of social networks in their association to drug equipment sharing among injection drug users: a review. Addiction 102:11, 1730-1739.
- 391Swati Pawa, Murray Ehrinpreis, Milton Mutchnick, James Janisse, Ravi Dhar, Firdous A. Siddiqui. (2007) Percutaneous Liver Biopsy Is Safe in Chronic Hepatitis C Patients With End-Stage Renal Disease. Clinical Gastroenterology and Hepatology 5:11, 1316-1320.
- 392Jason Smith, Steven-Huy B. Han. (2007) "True" weight-based dosing versus "flat" dosing of ribavirin: Will the WIN-R please come forward?. Hepatology 46:4, 953-956.
- 393Elisabeth Delarocque-Astagneau, Josiane Pillonel, Henriette De Valk, Alberto Perra, Syria Laperche, Jean-Claude Desenclos. (2007) An Incident Case–Control Study of Modes of Hepatitis C Virus Transmission in France. Annals of Epidemiology 17:10, 755-762.
- 394Stephen A. Harrison. (2007) Small Molecule and Novel Treatments for Chronic Hepatitis C Virus Infection. The American Journal of Gastroenterology 102:10, 2332-2338.
- 395Nizar N Zein. (2007) Hepatitis C in children: recent advances. Current Opinion in Pediatrics 19:5, 570-574.
- 396Ira M. Jacobson, Robert S. Brown, Jonathan McCone, Martin Black, Clive Albert, Michael S. Dragutsky, Firdous A. Siddiqui, Thomas Hargrave, Paul Y. Kwo, Louis Lambiase, Greg W. Galler, Victor Araya, Bradley Freilich, Joann Harvey, Louis H. Griffel, Clifford A. Brass, . (2007) Impact of weight-based ribavirin with peginterferon alfa-2b in african americans with hepatitis C virus genotype 1. Hepatology 46:4, 982-990.
- 397Jacques Baillargeon, Roger D. Soloway, David Paar, Thomas P. Giordano, Owen Murray, James Grady, Brie Williams, John Pulvino, Ben G. Raimer. (2007) End-Stage Liver Disease in a State Prison Population. Annals of Epidemiology 17:10, 808-813.
- 398O. Freudenreich, R. T. Gandhi, J. P. Walsh, D. C. Henderson, D. C. Goff. (2007) Hepatitis C in Schizophrenia: Screening Experience in a Community-Dwelling Clozapine Cohort. Psychosomatics 48:5, 405-411.
- 399S. S. Toussi, J. Abadi, M. Rosenberg, D. Levanon. (2007) Prevalence of Hepatitis B and C Virus Infections in Children Infected with HIV. Clinical Infectious Diseases 45:6, 795-798.
- 400Jorge L. Herrera. (2007) PRO: Management of Hepatitis C by Liver Disease Specialists. The American Journal of Gastroenterology 102:9, 1837-1839.
- 401Flavien Bernardin, Susan L. Stramer, Barbara Rehermann, Kimberly Page-Shafer, Stewart Cooper, David R. Bangsberg, Judith Hahn, Leslie Tobler, Michael Busch, Eric Delwart. (2007) High levels of subgenomic HCV plasma RNA in immunosilent infections. Virology 365:2, 446-456.
- 402Felice Piccinino, Nicola Coppola. (2007) Antiviral treatment of HCV-related cirrhosis. Digestive and Liver Disease 39, S96-S101.
- 403Judith Garrard, Veena Choudary, Holly Groom, Eric Dieperink, Mark L. Willenbring, Janet M. Durfee, Samuel B. Ho. (2007) Organizational change in management of hepatitis C: Evaluation of a CME program. Journal of Continuing Education in the Health Professions 26:2, 145-160.
- 404Scott Seronello, Muhammad Y. Sheikh, Jinah Choi. (2007) Redox regulation of hepatitis C in nonalcoholic and alcoholic liver. Free Radical Biology and Medicine 43:6, 869-882.
- 405Ashwani K. Singal, Bhupinder S. Anand. (2007) Mechanisms of Synergy Between Alcohol and Hepatitis C Virus. Journal of Clinical Gastroenterology 41:8, 761-772.
- 406Y. Zhou, Y. Lukes, J. Anderson, B. Fileta, B. Reinhardt, M. Sjogren. (2007) Hepatitis C virus E2 envelope protein induces dendritic cell maturation. Journal of Viral Hepatitis 0:0, 070901052026004-???.
- 407Hirofumi Uto, Joji Kurogi, Yuka Takahama, Kazunori Kusumoto, Katsuhiro Hayashi, Akio Ido, Michinori Kohara, Sherri O Stuver, Akihiro Moriuchi, Susumu Hasegawa, Makoto Oketani, Hirohito Tsubouchi. (2007) Alanine aminotransferase flare-up in hepatitis C virus carriers with persistently normal alanine aminotransferase levels in a hyperendemic area of Japan. Journal of Gastroenterology 42:8, 673-680.
- 408Verena Christen, Susan Treves, Francois H. T. Duong, Markus H. Heim. (2007) Activation of endoplasmic reticulum stress response by hepatitis viruses up-regulates protein phosphatase 2A. Hepatology 46:2, 558-565.
- 409Margarita Dehesa-Violante, Rafael Nuñez-Nateras. (2007) Epidemiology of Hepatitis Virus B and C. Archives of Medical Research 38:6, 606-611.
- 410Hugo R. Rosen, Scott J. Weston, KyungAh Im, Huiying Yang, James R. Burton, Henry Erlich, Jared Klarquist, Steven H. Belle, . (2007) Selective decrease in hepatitis C virus-specific immunity among African Americans and outcome of antiviral therapy. Hepatology 46:2, 350-358.
- 411Konrad Tang-Tat Fung, James Fung, Ching-Lung Lai, Man-Fung Yuen. (2007) Etiologies of chronic liver diseases in Hong Kong. European Journal of Gastroenterology & Hepatology 19:8, 659-664.
- 412Charles S. Whang, Ke-Qin Hu. (2007) Hepatitis C in patients with chronic kidney disease: Course and management. Current Hepatitis Reports 6:3, 96-102.
- 413Fitzroy W. Dawkins, Victor R. Gordeuk, Beverly M. Snively, Laura Lovato, James C. Barton, Ronald T. Acton, Gordon D. McLaren, Catherine Leiendecker-Foster, Christine E. McLaren, Paul C. Adams, Mark Speechley, Emily L. Harris, Sharon Jackson, Elizabeth J. Thomson. (2007) African Americans at Risk for Increased Iron Stores or Liver Disease. The American Journal of Medicine 120:8, 734.e1-734.e9.
- 414A. A. Butt, U. A. Khan, K. A. McGinnis, M. Skanderson, C. Kent Kwoh. (2007) Co-morbid medical and psychiatric illness and substance abuse in HCV-infected and uninfected veterans. Journal of Viral Hepatitis 0:0, 070729180316002-???.
- 415Vinod K. Rustgi. (2007) The epidemiology of hepatitis C infection in the United States. Journal of Gastroenterology 42:7, 513-521.
- 416Michal Kori, Orna Flidel-Rimon, Erica Sigler, Eric Shinwell, Esther Granot. (2007) Look-back study of Hepatitis C in teenagers after blood transfusions as neonates. Acta Paediatrica 96:7, 1050-1052.
- 417Hana Kerzman, Manfred S. Green, Eilat Shinar. (2007) Risk factors for hepatitisC virus infection among blood donors in Israel: a case-control study between native Israelis and immigrants from the former Soviet Union. Transfusion 47:7, 1189-1196.
- 418Kapil Gupta, Denise Romney, Muriel Briggs, Karen Benker. (2007) Effects Of A Brief Educational Program On Knowledge And Willingness To Accept Treatment Among Patients With Hepatitis C At Inner-City Hospitals. Journal of Community Health 32:4, 221-230.
- 419DAN H. BOURLA, ROBERT S. WIRTHLIN, NIRIT BOURLA, ANURAG GUPTA, DINU STANESCU-SEGALL, STEVEN D. SCHWARTZ, RUTH AXER-SIEGEL. (2007) RISK FOR EYE SPLASH INJURY DURING ADMINISTRATION OF INTRAOCULAR INJECTIONS. Retina 27:5, 609-612.
- 420Alexander V. Vlassov, Brent Korba, Kristine Farrar, Sampa Mukerjee, Attila A. Seyhan, Heini Ilves, Roger L. Kaspar, Devin Leake, Sergei A. Kazakov, Brian H. Johnston. (2007) shRNAs Targeting Hepatitis C: Effects of Sequence and Structural Features, and Comparision with siRNA. Oligonucleotides 17:2, 223-236.
- 421Wei-Shi Yeh, Edward P Armstrong, Grant H Skrepnek, Daniel C Malone. (2007) Peginterferon alfa-2a versus Peginterferon alfa-2b as Initial Treatment of Hepatitis C Virus Infection: A Cost-Utility Analysis from the Perspective of the Veterans Affairs Health Care System. Pharmacotherapy 27:6, 813-824.
- 422Martin Braddock. (2007) 11th Annual Inflammatory and Immune Diseases Drug Discovery and Development Summit. Expert Opinion on Investigational Drugs 16:6, 909-917.
- 423Isabelle Desombere, Hans Van Vlierberghe, Ola Weiland, Catharina Hultgren, Matti Sällberg, Juan Quiroga, Vicente Carreño, Geert Leroux-Roels. (2007) Serum levels of anti-NS4a and anti-NS5a predict treatment response of patients with chronic hepatitis C. Journal of Medical Virology 79:6, 701-713.
- 424Judith I. Tsui, David R. Bangsberg, Kathleen Ragland, Christopher S. Hall, Elise D. Riley. (2007) The Impact of Chronic Hepatitis C on Health-Related Quality of Life in Homeless and Marginally Housed Individuals with HIV.